<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/231346-n-3-3-substituted-pyrazolo-1-5-a-pyrimidin-7-yl-phenyl-sulfonamides-process-for-their-preparation-and-compositions-comprising-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:13:01 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 231346:N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING THEM</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING THEM</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention discloses compounds of formula I: wherein R1, R2 and R3 are as defined in the specification having specific affinity for the GABAA receptor, useful in the treatment and prevention of diseases modulated by the &amp;#945;1- and &amp;#945;2-GABAA receptors. The invention is also for the process for preparation of these compounds and compositions comprising them.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)<br>
PHENYLJ-SULFONAMIDES, PROCESS FOR THEIR PREPARATION<br>
AND COMPOSITIONS COMPRISING THEM<br>
Technical field<br>
This invention is diRected to ageR.ts with affinity foR<br>
GABA.v ReceptoR, moRe specifically to pyRazolo[1,5-a]<br>
pyRimidines.<br>
BackgRound of the invention<br>
GABAA ReceptoR (y-aminobutyRic acidA) is a pentameRic<br>
pRotein which foRms a membRane ion channel. GABAA ReceptoR<br>
is implicated in the Regulation of sedation, anxiety,<br>
muscle tone, epileptogenic activity and memoRy functions.<br>
These actions aRe due to defined subunits of GABAA.<br>
ReceptoR, paRticulaRly the α1- and α2-subunits.<br>
Sedation is modulated by the α1-subunit. Zolpidem is<br>
chaRacteRized by a high affinity foR the ax-ReceptoRs and<br>
its sedative and hypnotic action is mediated by these<br>
ReceptoRs in vivo. SimilaRly, the hypnotic action of<br>
zalepion is also mediated by the α1-ReceptoRs.<br>
The anxiolytic action of diazepam is mediated oy the<br>
enhancement of GAEAeRgic tRansmission in a population of<br>
neuRons expRessing the α2-ReceptoRs. This indicates that<br>
the α2-ReceptoRs aRe highly specific taRgets foR the<br>
tReatment of anxiety.<br><br>
Muscle Relaxation in diazepam is mainly mediated by α2-<br>
ReceptoRs, since these ReceptoRs exhibit a highly specific<br>
expRession in spinal coRd.<br>
The anticonvulsant effect of diazepam is paRtly due to α1-<br>
ReceptoRs. In diazepam, a memoRy-impaiRing compound,<br>
anteRogRade amnesia is mediated by ai-ReceptoRs.<br>
GABAA ReceptoR and its α1- and α2-subunits have been widely<br>
Reviewed by H. MohleR et al.(J. PhaRmacol. Exp. TheR., 300,<br>
2-8, 2002); H. MohleR et al.(CuRR. Opin. PhaRmacol., 1, 22-<br>
25, 2001); U. Rudolph et al.(NatuRe, 401, 796-800, 1999);<br>
and D.J. Nutt et al. (BR. J. PsychiatRy, 179, 390-396,<br>
2001).<br>
Diazepam and otheR classical benzodiazepines aRe<br>
extensively used as anxiolytic agents, hypnotic agents,<br>
anticonvulsants and muscle Relaxants. TheiR side effects<br>
include anteRogRade amnesia, decRease in motoR activity and<br>
potentiation of ethanol effects.<br>
In this  context,  the compounds of this invention aRe <br>
ligands of α1- and α2-GABAA ReceptoR foR theiR clinical<br>
application  in  sleep  disoRdeRs,  pRefeRably  insomnia,<br>
anxiety and epilepsy.<br>
Insomnia is a highly pRevalent disease. Its chRonicity<br>
affects 10% of the population and 30% when tRansitoRy<br>
insomnia is computed as well. Insomnia descRibes the<br>
tRouble in getting to sleep oR staying asleep and is<br>
associated with next-day hangoveR effects such as<br>
weaRiness,   lack  of  eneRgy,   low  concentRation  and<br><br>
iRRitability. The social and health impact of this<br>
complaint is impoRtant and Results in evident socioeconomic<br>
RepeRcussions.<br>
PhaRmacological theRapy in the management of insomnia<br>
fiRstly included baRbituRates and chloRal hydRate, but<br>
these dRugs elicit numeRous known adveRse effects, foR<br>
example, oveRdose toxicity, metabolic induction, and<br>
enhanced dependence and toleRance. In addition, they affect<br>
the aRchitectuRe of sleep by decReasing above all the<br>
duRation and the numbeR of REM sleep stages. LateR,<br>
benzodiazepines meant an impoRtant theRapeutic advance<br>
because of theiR loweR toxicity, but they still showed<br>
seRious pRoblems of dependence, muscle Relaxation, amnesia<br>
and Rebound insomnia following discontinuation of<br>
medication.<br>
The  latest  known  theRapeutic  appRoach  has  been  the<br>
intRoduction  of  non-benzodiazepine  hypnotics,  such  as<br>
pyRRolo[3,4-b]pyRazines     (zopiclone),     imidazo[1,2-a]<br>
pyRidines   (Zolpidem)   and,   finally,   pyRazolo[1,5-a]<br>
pyRimidines  (zaleplon).  LateR,  two new pyRazolo[1,5-a]<br>
pyRimidines,  indiplon and ocinaplon,  have enteRed into<br>
development, the latteR with RatheR anxiolytic action. All<br>
these compounds show a Rapid sleep induction and have less<br>
next-day hangoveR effects, loweR potential foR abuse and<br>
loweR Risk of Rebound insomnia than benzodiazepines. The<br>
mechanism of action of these compounds is the alosteRic<br>
activation  of  GABAA ReceptoR  thRough  its  binding  to<br>
benzodiazepine binding site (C. F. P. GeoRge, The Lancet,<br>
358, 1623-1626, 2001) . While benzodiazepines aRe unspecific<br>
ligands  at  GABAA  ReceptoR  binding  site,  Zolpidem and<br>
zaleplon  show  a  gReateR  selectivity  foR  α1-subunit.<br><br>
Notwithstanding that, these dRugs still affect the<br>
aRchitectuRe of sleep and may induce dependence in long-<br>
teRm tReatments.<br>
In US patent documents No. 4,626,538 (zaleplon), No.<br>
4,654,347, 6,399,621 (indiplon) and EuRopean Patent No.<br>
129,847 (ocinaplon) hypnotic pyRazolo[1, 5-a]pyRimidines aRe<br>
disclosed.	<br>
ReseaRch foR new active compounds in the management of<br>
insomnia answeRs an undeRlying health need, because even<br>
Recently intRoduced hypnotics still affect the aRchitectuRe<br>
' of sleep and may induce dependence in long-teRm tReatments.<br>
It is theRefoRe desiRable to focus on the development of<br>
new hypnotic agents with a loweR Risk of side effects.<br>
Thus, the pResent invention is diRected to new N-[3-(3-<br>
substituted-pyRazolo[1,5-a]pyRimidin-7-yl)-phenyl]-<br>
sulfonamides  which   aRe   active  veRsus   GABAA  and,<br>
paRticulaRly, veRsus its ai- and a2-subunits. Consequently,<br>
the compounds of this invention aRe useful in the tReatment<br>
and pRevention of all those diseases mediated by GABAA<br>
ReceptoR α1 and α2-subunits. Non-limitative examples of<br>
such diseases aRe sleep disoRdeRs, pRefeRably insomnia,<br>
anxiety  and  epilepsy.  Non-limitative  examples  of  the<br>
Relevant indications of the compounds of this invention aRe<br>
all those diseases oR conditions,  such as insomnia oR<br>
anesthesia, in which an induction of sleep, an induction of<br>
sedation oR an induction of muscle Relaxation aRe needed.<br><br>
Detailed descRiption of the invention<br>
The pResent invention Relates to novel N-[3-(3-substituted-<br>
pyRazolo[1,5-a]pyRimidin-7-yl)-phenyl]-sulfonamides of<br>
foRmula (I) <br>
and theiR phaRmaceutically acceptable salts;<br>
wheRein<br>
R1 is selected fRom the gRoup consisting of alkyl (C1-C6),<br>
alkenyl (C2-C6) ,ω ,ω,ω-tRifluoRoalkyl (C1-C6),  cycloalkyl(C3-<br>
C6),  cycloalkyl (C3-C6) alkyl (C1-C6),  -O-alkyl (C1-C6),  -NH-<br>
alkyl(C1-C6),  -N(dialkyl(C1-C6) ) ,  alkyl (CR-C6)-O-alkyl (C1-<br>
C6), alkyl (C1-C6)-NH-alkyl (C1-C6) , alkyl (C1-C6) -N (dialkyl (C1-<br>
C6) ) , phenyl, monosubstituted phenyl, disubstituted phenyl,<br>
phenylalkyl (C1-C6), phenylalkenyl (C2-C6), fuRyl, substituted<br>
fuRyl,  isoxazolyl,  substituted  isoxazolyl,  pyRazolyl,<br>
substituted  pyRazolyl,  thienyl,  substituted  thienyl,<br>
thiazolyl, substituted thiazolyl, pyRidyl and substituted<br>
pyRidyl;<br>
R2 is selected fRom the gRoup consisting of hydRogen,<br>
alkyl (C1-C6) ,     alkenyl (C2-C6) ,     alkynyl (C2-C6)     and<br>
cycloalkyl (C3-C6) <br>
oR else<br>
R1 and R2 foRm a cycle having the stRuctuRe:<br><br><br>
wheRein n is an integeR 1, 2 oR 3 inclusive;<br>
R3 is selected fRom the gRoup consisting of hydRogen,<br>
halogen,  alkyl (C1-C6) ,  cycloalkyl (C3-C6) ,  alkenyl (C2-C6) ,<br>
alkynyl(C2-C6) ,  -O-alkyl (C1-C6) ,     halo-alkyl (C1-C6) ,  -CN, -'<br>
SO2-R4,  -NH-R4,  -NR4R5,  -COR6,  -CO-NHR6,  -COOR6,  -C(NR7)R6,<br>
j<br>
phenyl, substituted phenyl, heteRoaRyl and substituted<br>
heteRoaRyl;	<br>
R4 and R5 aRe independently selected fRom the gRoup<br>
consisting of alkyl (C1-C6) , cycloalkyl (C3-C6) , aRyl and<br>
heteRoaRyl;<br>
R6 is selected fRom the gRoup consisting of hydRogen,<br>
alkyl (C1-C6) , alkenyl (C2-C6) , alkynyl (C2-C6) , cycloalkyl(C3-<br>
c6) , phenyl, substituted phenyl, fuRyl, substituted fuRyl,<br>
thienyl, substituted thienyl, thiazolyl, substituted<br>
thiazolyl, pyRidyl and substituted pyRidyl;<br>
R7 is selected fRom the gRoup consisting of alkyl (Ci-C6) ,<br>
cycloalkyl (C3-C6) ,  -OH,   -O-alkyl (C1-C6) ,  alkyl (C1-C6) -0-<br>
alkyl(C1-C6) ,   alkyl (C1-C6)-NH-alkyl (Cx-Cg) ,   alkyl (Cx-C6) -<br>
N(dialkyl(Ci-C6) ), phenyl, monosubstituted phenyl,  fuRyl,<br>
thienyl, thiazolyl and pyRidyl; and<br>
R1 is selected fRom the gRoup consisting of hydRogen,<br>
alkyl (C1-C3) ,  cycloalkyl (C3-C6) ,  aRyl  and substituted oR<br>
unsubstituted heteRoaRyl;<br>
with the pRoviso that:<br>
Ri may simultaneously not be p-tolyl and R2 methyl and R3<br>
.benzoyl; and<br>
Ri may simultaneously not be p-tolyl and R2 ethyl and R3<br>
fuRyl-2-caRbonyl.<br><br>
US Patent No. 4.654.347 (Example 80) discloses N-[3-(3-<br>
benzoyl-pyRazolo[1,5-a]pyRimidin-7-yl)phenyl]-N,4-dimethyl<br>
-benzenesulfonamide  and  EuRopean  Patent  No.  129.847<br>
(Example 166) discloses N-ethyl-N-[3-[3-(2-fuRylcaRbonyl) -<br>
pyRazolo[1,5-a]pyRimidin-7-yl]phenyl]-4-methyl-benzene-<br>
sulfonamide. These compounds aRe meRely Recited in the<br>
above patents as synthetic inteRmediates, and they aRe not<br>
consideRed phaRmacologically active substances. This fact,<br>
theRefoRe, does not suggest that analog compounds, like<br>
those in the instant invention, may be theRapeutically<br>
inteResting, which finding has unexpectedly been discoveRed<br>
by the applicants. These compounds, which aRe compRised in<br>
the geneRal foRmula (I) , have puRposely been thus excluded<br>
fRom the scope of this invention.<br>
Ri is pRefeRably selected fRom alkyl (Ci-Cs);ω,ω,ω-<br>
tRifluoRoalkyl(Ci-C6) ; phenyl; phenyl substituted with 1 oR<br>
2 gRoups which aRe independently selected fRom halogen (in<br>
paRticulaR fluoRo and chloRo), cyano, N02, Oalkyl (C1-C6) and<br>
alkyl (Ci-C6) ; phenylalkenyl (C2-Cg) ; cycloalkyl (C3-C6) ;<br>
cycloalkyl (C3-C6) alkyl (Ci-C6) ;	phenylalkyl (Ci~C6) ;<br>
alkenyl (C2-C6) ; isoxazolyl which may be substituted with 1<br>
oR 2 alkyl (Ci-C6) ; fuRyl which may be substituted with 1 oR<br>
2 alkyl(C1-C6) ;  fuRyl which may be substituted with 1<br>
alkyl(Ci-C6)  and 1 tRifluoRomethyl;■ thiazolyl which may<br>
substituted with 1 oR 2 alkyl (Ci-C6) ; pyRazolyl which may<br>
be substituted with 1, 2 oR 3 alkyl (Ci-C6) ; thienyl which<br>
may be substituted with 1 oR 2 alkyl (Ci-Ce) and pyRidyl<br>
which may be substituted with 1 oR 2 4-moRpholinyl gRoups;<br>
oR R1 and R2 togetheR foRm the above mentioned cycle<br>
wheRein n and R8 aRe as defined above.<br><br>
R2 is pRefeRably selected fRom H, alkyl (Ci-C6) ,<br>
cycloalkyl (C3-C6) and alkinyl (C2-C6) , oR R2 foRms togetheR<br>
with R1 the above mentioned cycle wheRein n and R8 aRe as<br>
defined above.<br>
R3 is pRefeRably selected fRom H, CN and COR6 wheRein R6 is<br>
selected fRom phenyl which may be substituted with 1 oR 2<br>
gRoups which aRe independently selected fRom halogen (in<br>
paRticulaR fluoRo oR chloRo), alkyl (Ci-C6) and Oalkyl(Ci-<br>
C6) ; thienyl; pyRidyl and oxadiazolyl which may be<br>
substituted with alkyl (Ci-C6) .<br>
A pRefeRRed embodiment Relates to the compounds of foRmula<br>
I wheRein R3 is cyano, Ri is selected fRom alkyl (Ci-C6) ,<br>
phenyl and phenyl substituted with an Oalkyl(C1-C6) gRoup,<br>
and R2 is selected fRom alkyl (Ci-C6), cycloalkyl (C3-C6) and<br>
alkynyl(C2-C6) .<br>
A fuRtheR pRefeRRed embodiment Relates to compounds of<br>
foRmula I, wheRein R3 is thiophene caRbonyl, in paRticulaR<br>
thiophene-2-caRbonyl,  Ri  is  selected  fRom alkyl (C1-C6) ;<br>
pheylalkenyl (C2-C6) ;  co,co,co-tRifluoRoalkyl (d-C6) ;  phenyl;<br>
phenyl  substituted  with  1  oR  2  gRoups  which  aRe<br>
independently selected fRom halogen (in paRticulaR fluoRo<br>
and chloRo), cyano, Oalkyl(Ci-C6) and nitRo; phenylalkyl(Ci-<br>
C6);   cycloalkyl (C3-C6) ;   alkenyl (C2-C6) ;   cycloalkyl(C3-<br>
C6) alkyl (C1-C6) ; isoxazolyl substituted with 1 oR 2 alkyl<br>
(Ci-C6); fuRyl substituted with 1 oR 2 gRoups independently<br>
selected fRom alkyl (Ci-C6) and w, w, w-tRif luoRoalkyl {Ci-Ce) ;<br>
thiazolyl substituted with 1 oR 2 alkyl (Ci-C6) ; pyRidyl<br>
which is substituted with a 4-moRpholinyl gRoup; thienyl;<br>
and pyRazolyl substituted with 1, 2 oR 3 alkyl (Ci-Cg) , and<br>
R2 is selected fRom H, alkyl (C1-C6) , cycloalkyl (C3-C6) and<br>
alkynyl(C2-C6) .<br><br>
A fuRtheR pRefeRRed embodiment Relates to compounds of<br>
foRmula I, wheRein R3 is selected fRom benzoyl, wheRein the<br>
phenyl gRoup may be substituted with halogen (in paRticulaR<br>
fluoRo oR chloRo) , alkyl (Ci-C6) and Oalkyl (Ci-C6) ;<br>
oxadiazolyl which is substituted with alkyl (C1-C0) and<br>
pyRidylcaRbonyl; R1 is alkyl (d-C6) and R2 is H, alkyl (Ci-C6)<br>
oR alkynyl (C2-C6) .<br>
PRefeRably, the pResent invention Relates to new N-[3-(3-<br>
substituted-pyRazolo[1,5-a]pyRimidin-7-yl)-phenyl]-<br>
sulfonamides of foRmula (I) wheRein R1 is selected fRom the<br>
gRoup consisting of methyl, ethyl, n-pRopyl, i-pRopyl, n-<br>
butyl,  2-phenylethenyl,  2,2,2-tRifluoRoethyl,  phenyl,  2-<br>
cloRophenyl,     3-cloRophenyl,     4-cloRophenyl,     2,4-<br>
dicloRophenyl,   3,4-dichloRophenyl,   2-cyanophenyl,   3-<br>
cyanophenyl, 4-cyanophenyl, 4-methoxyphenyl, 3-nitRophenyl,<br>
4-nitRophenyl, 2-thienyl, 5-methyl-4-isoxazolyl, 5-methyl-<br>
2-tRifluoRomethyl-3-fuRyl,     4-(4-moRpholinyl)-3-pyRidyl,<br>
2,4-dimethyl-5-thiazolyl, cyclopRopyl, benzyl, vinyl, 3,5-<br>
dimethyl-4-isoxazolyl,   1,3,5-tRimethyl-4-pyRazolyl   and<br>
cyclopentylmethyl; R2 is selected fRom the gRoup consisting<br>
of hydRogen, methyl, ethyl, n-pRopyl, i-pRopyl, n-butyl,<br>
cyclopRopyl  and  2-pRopynyl,  oR  R1  and  R2  foRm  in<br>
conjunction with the -N-SO2- gRoup an isothiazolidine-1,1-<br>
dioxide Ring, in such a way that R1 and R2 foRm togetheR a<br>
1,3-pRopylene gRoup, and R3 is selected fRom a cyano gRoup,<br>
a benzoyl gRoup, a 4-fluoRobenzoyl gRoup, a 4-methylbenzoyl<br>
gRoup,   a  4-methoxybenzoyl  gRoup,   a  5-methyl-l,2,4-<br>
oxadiazol-3-yl  gRoup,  a  pyRidyl-2-caRbonyl  gRoup,  a<br>
pyRidyl-4-caRbonyl gRoup and a thiophene-2-caRbonyl gRoup.<br><br>
"HeteRoaRyl" means 5- oR 6-membeRed aRomatic heteRocyclic<br>
gRoups  containing  1,  2  oR  3  heteRoatoms  which  aRe<br>
independently fRom each otheR selected fRom N, 0 and S.<br>
Examples foR heteRoaRyl gRoups aRe pyRidyl, pyRimidinyl,<br>
tRiazinyl, pyRRolyl, thienyl, fuRyl, oxazolyl, thiazolyl,<br>
imidazolyl, oxadiazolyl.<br>
"ARyl" means pRefeRably phenyl oR naphthyl.<br>
"Halogen" oR "halo" means F, C1, BR oR I, pRefeRably F oR<br>
C1.<br>
"Cycloalkyl (C3-C6)" pRefeRably means cyclopRopyl,<br>
cyclopentyl oR cyclohexyl.<br>
"Substituted" (including mono- and di- substituted) means<br>
that the gRoup in question caRRies 1, 2 oR 3 substituents<br>
which aRe independently fRom each otheR selected fRom<br>
alkyl (Ci-Cg) , Oalkyl (Ci-C6) , halogen, CN and N02. In case of<br>
heteRoaRyl gRoups the substituent may also be attached to a<br>
heteRo nitRogen atom.<br>
Alkyl gRoups (also in -Oalkyl, -NHalkyl etc.) include<br>
stRaight chain and bRanched gRoups and pRefeRably have 1 to<br>
4 caRbon atoms.<br>
The teRm "phaRmaceutically acceptable salt" used heRein<br>
encompasses any salt foRmed fRom oRganic and inoRganic<br>
acids,  such  as  hydRobRomic,  hydRochloRic,  phosphoRic,<br>
nitRic,    sulfuRic,    acetic,    adipic,    aspaRtic,<br>
benzenesulfonic, benzoic, citRic, ethanesulfonic, foRmic,<br>
fumaRic,  glutamic,   lactic,  maleic,  malic,   malonic,<br><br><br><br><br><br>
N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-phenyl]-N-<br>
pRopyl-2-pRopanesulfonamide/<br>
N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-phenyl]-N-<br>
pRop-2-inyl-ethanesulfonamide;<br>
N-methyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-ethyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-ethyl-N-{3-[3-(pyRidin-2-caRbpnyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo[l,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-methyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-ethyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-ethyl-N-{3-[3-(peRidin-4-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo   [1, 5-<br>
a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide ;<br>
N-pRop-2-inyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-ethyl-M-{3-[3-(fluoRobenzene-4-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br><br>
N-methyl-N-{3-[3-(fluoRobenZene-4-caRbonyl)-pyRazolo[l,<br>
a]pyRimidin-7-yll-phenyl}-ethanesulfonamide;<br>
N-ethyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-y]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-pyRazolo<br>
[l,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-ethyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-ethyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N~methyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-ethyl-N~{3-[3-(4-methylbenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-ethyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-f 3-[3-(4-methylbenzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide;<br><br>
N-methyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a]pyRimidin-7-yl]-<br>
phenyl}-methanesulfonamide;<br>
N-ethyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a]pyRimidin-7-yl]-<br>
phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a]pyRimidin-7-yl]-<br>
phenyl}-ethanesulfonamide;<br>
N-ethyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a]pyRimidin-7-yl]-<br>
phenyl}-ethanesulf onamide; <br>
N-pRop-2-inyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a]pyRimidin-7-<br>
yl]-phenyl}-ethanesulfonamide;<br>
N-pRop-2-inyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a] pyRimidin-<br>
7-yl]-phenyl}-methanesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-2-phenylethenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-2,2,2-tRifluoRoethane-sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-2-chloRobenzenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-3-chloRobenzenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-4-chloRobenzenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-2,4-dichloRobenzene-sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-3,4-dichloRobenzene-sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-2-cyanobenzenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-3-cyanobenzenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-4-cyanobenzenesulfonamide;<br><br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-3-nitRobenzenesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-4-nitRobenznesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-2-thiophenesulfonamide;<br>
N-methyl-N-{3-[3- (thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-5-methyl-4-isoxazolyl-sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-2-tRifluoRomethyl-5-methyl-3-<br>
fuRylsulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-6-(moRpholin-4-yl)-3-<br>
pyRidylsulfonamide;<br>
N-methyl-N-{3-[3- (thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-2,4-dimethyl-5-thiazolyl-<br>
sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-cyclopRopylsulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-benzylsulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}—vinylsulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-3,5-dimethyl-4-isoxazolyl-<br>
sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-l,3,5-tRimethyl-4-pyRazolyl-<br>
sulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-pRopanesulfonamide;<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-butanesulfonamide;<br><br><br>
AnotheR embodiment of the pResent invention is to pRovide -a<br>
pRocess foR pRepaRing the compounds of foRmula (I) and<br>
theiR phaRmaceutically acceptable salts.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing diseases associated with<br>
GABAA ReceptoR modulation in a mammal which compRises<br>
administeRing to said mammal an effective amount of a<br>
compound of foRmula (I) oR a phaRmaceutically acceptable<br>
salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing diseases associated with<br>
CXI-GABAA ReceptoR modulation in a mammal which compRises<br>
administeRing to said mammal an effective amount of a<br>
compound of foRmula (I) oR a phaRmaceutically acceptable<br>
salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing diseases associated with<br>
(X2-GABAA ReceptoR modulation in a mammal which compRises<br>
administeRing to said mammal an effective amount of a<br>
compound of foRmula (I) oR a phaRmaceutically acceptable<br>
salt theReof.<br><br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing anxiety in a mammal which<br>
compRises administeRing to said mammal an effective amount<br>
of a compound of foRmula (I) oR a phaRmaceutically<br>
acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing epilepsy in a mammal <br>
which compRises administeRing to said mammal an effective<br>
amount of a compound of foRmula (I) oR a phaRmaceutically<br>
acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing sleep disoRdeRs in a<br>
mammal which compRises administeRing to said mammal an<br>
effective amount of a compound of foRmula (I) oR a<br>
phaRmaceutically acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR tReating oR pReventing insomnia in a mammal<br>
which compRises administeRing to said mammal an effective<br>
amount of a compound of foRmula (I) oR a phaRmaceutically<br>
acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR inducing sedation-hypnosis in a mammal which<br>
compRises administeRing to said mammal an effective amount<br>
of a compound of foRmula (I) oR a phaRmaceutically<br>
acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR inducing anesthesia in a mammal which compRises<br>
administeRing to said mammal an effective amount of a<br><br>
compound of foRmula (I) oR a phaRmaceutically acceptable<br>
salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR modulating the necessaRy time to induce sleep<br>
and its duRation in a mammal which compRises administeRing<br>
to said mammal an effective amount of a compound of foRmula<br>
(I) oR a phaRmaceutically acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
method foR inducing muscle Relaxation in a mammal which<br>
compRises administeRing to said mammal an effective amount<br>
of a compound of foRmula (I) oR a phaRmaceutically<br>
acceptable salt theReof.<br>
AnotheR embodiment of the pResent invention is to pRovide a<br>
phaRmaceutical composition containing a compound of foRmula<br>
(I)  oR a phaRmaceutically  acceptable salt  theReof  in<br>
association with theRapeutically ineRt caRRieRs.<br>
The compositions include those suitable foR oRal, Rectal<br>
and paRenteRal (including subcutaneous, intRamusculaR, and<br>
intRavenous) administRation, although the most suitable<br>
Route will depend on the natuRe and seveRity of the<br>
condition being tReated. The most pRefeRRed Route of the<br>
pResent invention is the oRal Route. The compositions may<br>
be conveniently pResented in unit dosage foRm, and<br>
pRepaRed by any of the methods well known in the aRt of<br>
phaRmacy.<br>
The active compound can be combined with a phaRmaceutical<br>
caRRieR accoRding to conventional phaRmaceutical compoun-<br>
ding techniques. The caRRieR may take a wide vaRiety of<br><br>
foRms depending on the foRm of the pRepaRation desiRed foR<br>
administRation, e.g. oRal oR paRenteRal (including intRa-<br>
venous injections oR infusions). In pRepaRing the compo-<br>
sitions foR oRal dosage foRm any of the usual phaRma-<br>
ceutical media may be employed. Usual phaRmaceutical media<br>
include,  foR example,  wateR,  glycols,  oils,  alcohols,<br>
flavoRing agents, pReseRvatives, coloRing agents, and the<br>
like in the case of oRal liquid pRepaRations (such as foR<br>
example, suspensions, solutions, emulsions and elixiRs);<br>
aeRosols; oR caRRieRs such as staRches,  sugaRs,  micRo-<br>
cRystalline  cellulose,  diluents,   gRanulating  agents,  /<br>
lubRicants, bindeRs, disintegRating agents and the like,<br>
in the case of oRal solid pRepaRations  (such as foR<br>
example, powdeRs, capsules,  and tablets) with the oRal<br>
solid pRepaRations being pRefeRRed oveR the oRal liquid<br>
pRepaRations.<br>
Because 'of theiR ease of administRation, tablets and<br>
capsules RepResent the most advantageous oRal dosage unit<br>
foRm, in which case solid phaRmaceutical caRRieRs aRe<br>
employed. If desiRed, tablets may be coated by standaRd<br>
aqueous oR nonaqueous techniques.	,<br>
A suitable dosage Range foR use is fRom about 0.01 mg to<br>
about 100,00 mg total daily dose, given as a once daily<br>
administRation oR in divided doses if RequiRed.<br>
The compounds of geneRal foRmula (I) may be pRepaRed<br>
accoRding to the Reaction shown in Scheme 1.<br><br><br>
Scheme 1<br>
R1, R2 and R3 aRe as descRibed above and Q is an appRopRiate<br>
leaving gRoup consisting of N(dialkyl(Ci-C6) ) , alkylthio(Ci~<br>
Ce) and alkoxy (C1-C6) ■ PRefeRably Q is selected fRom the<br>
gRoup consisting of dimethylamino, methylthio oR methoxy.<br>
The Reaction of aminopyRazole of geneRal foRmula (III) with<br>
appRopRiately substituted l-aRyl-2-pRopen-l-one   (II)  is<br>
caRRied out in an ineRt polaR pRotic oR apRotic solvent<br>
such  as  glacial  acetic  acid,   ethanol,   methanol,<br>
dimethylfoRmamide oR dimethylsulfoxide at a tempeRatuRe<br>
Ranging fRom 50° to 130°C. AfteR elapsing seveRal houRs<br>
(Reaction time), the solvent is Removed and the Residue<br>
obtained is paRtitioned between an aqueous solution of<br>
sodium bicaRbonate and dichloRomethane. The cRude Resulting<br>
fRom evapoRating the oRganic layeR to dRyness may be<br>
puRified by one of the following methods: (a) silica gel<br>
chRomatogRaphy   using ethyl acetate oR dichloRomethane<br>
/methanol as eluent; oR (b) cRystallization in a suitable<br>
solvent (ethyl acetate, ethanol, methanol, etc.).<br>
The inteRmediate of foRmula (II) when Q is dimethylamino<br>
[inteRmediate (VI)] can be obtained following the Reaction<br>
sequence shown in Scheme 2<br><br><br>
Scheme 2<br>
wheRein R1 and R2 aRe as descRibed above.<br>
The sulfonamides of foRmula (IV) aRe pRepaRed accoRding to<br>
the method descRibed by R. H. Uloth et al (J. Med. Chem. 9,<br>
88-96, 1966).<br>
The alkylation of the sulfonamides  (IV)  leading to the<br>
inteRmediates of foRmula (V) is peRfoRmed, in accoRdance<br>
with methods well known by expeRts in ORganic ChemistRy,<br>
via foRmation of an anion and subsequent Reaction with an<br>
alkyl halide.<br>
The enaminones of foRmula (VI) aRe pRepaRed accoRding to<br>
geneRal synthetic pRoceduRes of enamines descRibed by J. M.<br>
Domagala et al (J. HeteRocyclic Chem., 26(4), 1147-58,<br>
1989); and K. Sawada et al (Chem. PhaRm. Bull., 49(7), 799-<br>
813, 2001) by Reacting an acetophenone with N,N-<br>
dimethylfoRmamide dimethylacetal (DMFDMA) oR BRedeReck's<br>
Reagent (teRt-butoxybis(dimethylamino)methane).<br><br>
The inteRmediates of foRmula (II), when Q is dimethylamino<br>
and R2 is methyl (VII), can alteRnatively be pRepaRed<br>
accoRding to Scheme 3.<br><br>
Scheme 3<br>
The conveRsion of (IV) into (VII) leads to the foRmation of<br>
the enaminone and, simultaneously, the foRmation of the N-<br>
methyl-sulfonamide as a Result of the use of the pRopeRties<br>
of the N,N-dimethylfoRmamide dimethyl acetal as a<br>
methylating agent.<br>
InteRmediate (VII) can also be pRepaRed accoRding to Scheme<br>
4.<br><br>
Scheme 4<br><br>
The advantage of this pRocess is based on the fact that the<br>
foRmation of the sulfonamide takes place in the last state<br>
of pRocess. As a Result, the total numbeR of Reaction steps<br>
is Reduced in the pRepaRation of laRge seRies of pRoducts.<br>
MoReoveR, as shown in the scheme, the conveRsion of (VIII)<br>
into (IX) leads to thRee following Reactions in a one-pot<br>
pRocess: (a) foRmation of the anaminone; (b) methylation of<br>
the tRifluoRoacetamide; and (c) deacylation yielding the N-<br>
methylated amine. The subsequent Reaction of (IX) with the<br>
coRResponding sulfonic acid chloRide leads to obtaining<br>
inteRmediates (VII).<br>
The pRepaRation of inteRmediates (VII) by Reaction between<br>
inteRmediates (IV) and N,N-dimethylfoRmamide dimethyl<br>
acetal has not eveR disclosed in the chemical liteRatuRe<br>
and is anotheR embodiment of the pResent invention.<br>
SimilaRly, the pRepaRation of inteRmediates (VII) by<br>
Reaction between N-(3-acetylphenyl)-2,2, 2-tRifluoRo-<br>
acetamide (VIII) and N,N-dimethylfoRmamide dimethyl acetal,<br>
followed by the foRmation of the sulfonamide by Reaction<br>
with the coRResponding sulfonic acid chloRide have not<br>
disclosed eitheR in the chemical liteRatuRe and is anotheR<br>
embodiment of the pResent invention.<br>
FRom the compounds of geneRal foRmula (I) it is possible to<br>
obtain theiR phaRmaceutically acceptable salts by tReatment<br>
with the coRResponding acids.<br>
The applicants have discoveRed that the compounds of the<br>
pResent invention have a high affinity foR α1- and.α2-GABAA<br>
ReceptoRs as shown in Tables 1 and 2.  These in    vitRo<br><br>
Results aRe consistent with those in   vivo  Results obtained<br>
in sedation-hypnosis tests (Table 3).<br>
In accoRdance with the Results obtained, ceRtain compounds<br>
of the pResent invention have suRpRisingly evidenced<br>
phaRmacological activity both in vitRo and in vivo, which<br>
has been similaR to oR higheR than that of pRioR-aRt<br>
compounds. All these Results suppoRt!theiR use in diseases <br>
oR conditions modulated by α1- and α2-GABAA ReceptoRs, such<br>
as insomnia oR anesthesia, in which an induction of sleep,<br>
an induction of sedation oR an induction of muscle<br>
Relaxation aRe needed.<br>
The  phaRmacological  activity  of  the  compounds  of  the<br>
pResent invention has been deteRmined as shown below.<br>
Ligand-binding  assays.    DeteRmination   of   the   affinity<br>
of test   compounds foR α1-  and α2-GABAA ReceptoR.<br>
Male SpRague-Dawley Rats weighing 200-250 g at the time of<br>
expeRiment weRe used. AfteR decapitation of the animal, the<br>
ceRebellum (tissue that mostly contains α1-GABAA ReceptoR)<br>
and  spinal  coRd  (tissue that mostly contains α2-GABAA<br>
ReceptoR)  weRe  Removed.  The  membRanes  weRe  pRepaRed<br>
accoRding to the method by J. Lameh et al. (PRog. NeuRo-<br>
PsychophaRmacol. Biol. PsychiatRy, 24, 979-991, 2000). Once<br>
the tissues weighed, they weRe suspended in 50 mM TRis-HCl<br>
(pH 7.7), 1:40 (v/v), homogenized and then centRifuged at<br>
20000     g foR  10 min at 7°C.  The Resulting pellet was<br>
Resuspended undeR the  same  conditions  and centRifuged<br>
again. The pellet was finally Resuspended on a minimum<br>
volume and kept at -80°C oveRnight. On the next day, the<br><br>
pRocess was Repeated until the final pellet was Resuspended<br>
at a Ratio of 1:10 (v/v).<br>
Affinity  was  deteRmined  by  competitive  tests  using<br>
Radiolabeled flumazenil as ligand. The tests weRe peRfoRmed<br>
accoRding to the methods descRibed by S. ARbilla et al.<br>
(EuR. J. PhaRmacol., 130, 257-263, 1986); and Y. Wu et al.<br>
(EuR. J. PhaRmacol., 278,  125-132,  1995). The membRanes<br>
containing the study ReceptoRs, flumazenil (Radiolabeling "<br>
at  a  final  concentRation  of  1  nM)  and  ascending<br>
concentRations of test compounds (in a total volume of 500<br>
μ1    in 50 nM [ph 7.4] TRis-HCl buffeR) weRe incubated. <br>
Simultaneously, the membRanes weRe only incubated with the<br>
Radiolabeled flumazenil (total binding, 100%) and in the<br>
pResence of an elevated concentRation of unRadiolabeled<br>
flumazenil   (non-specific  binding,   %   estimation  of<br>
Radiolabeled ligand). The Reactions staRted on adding the<br>
Radiolabeled ligand followed by incubation foR 60 minutes<br>
at 0°C. At the end of the incubation peRiod, the tubes weRe<br>
filteRed using a BRandel Mod. M-48R haRvesteR and then<br>
washed thRee times with cold test buffeR. The haRvesteR was<br>
fitted with a GF/B filteR that Retained the membRanes<br>
containing the ReceptoRs and the Radiolabeled ligand which &gt;<br>
had been bound to the ReceptoRs. Then the filteRs weRe<br>
Removed and left till dRy. Once dRied, the filteRs weRe<br>
cut, placed in vials with scintillation liquid and left<br>
undeR stiRRing oveRnight. The next day the filteRs weRe<br>
counted using a PackaRd Mod. TRicaRb scintillation counteR.<br>
FoR analysis of the Results the peRcentage of specific<br>
binding  foR  eveRy concentRation of test  compound was<br>
calculated as follows:<br>
% specific binding = (X-N/T-N) x 100<br><br>
wheRe,<br>
X:  amount of bound ligand foR eveRy concentRation of<br>
compound.<br>
T: total binding, maximum amount bound to the Radiolabeled<br>
ligand.<br>
N:  non-specific binding,  amount of Radiolabeled ligand<br>
bound in a non-specific way iRRespective of the ReceptoR<br>
used.<br>
EveRy concentRations of compound weRe tested in duplicate<br>
and  theiR  mean  values  weRe  used  to  deteRmine  the<br>
expeRimental values  of  %  specific binding veRsus  the<br>
concentRation of compound. The values thus attained weRe<br>
fitted to a equation foR competitive assays  (SigmaPlot,<br>
SPSS Inc.) and the IC50 values (concentRation of compound<br>
able to inhibit by 50% the specific binding). Inhibition<br>
constants  (Ki)  weRe  calculated  fRom  the  IC50  values<br>
accoRding to Cheng-PRusoff's foRmula (Y. Cheng y W. H.<br>
PRusoff, Biochem. PhaRmacol., 22(23), 3099-3108, 1973). The<br>
affinity data foR subunit α2  aRe alteRnatively expRessed as<br>
% inhibition at the concentRations of 10-5 M and 10-7 M. The<br>
Results of these tests aRe given in Tables 1 and 2.<br><br><br><br><br><br><br><br>
In   vivo   deteRmination   of pRedictive   sedative-hypnotic<br>
action.<br>
The in   vivo   effects of these compounds weRe assessed by a<br>
pRedictive sedation-hypnosis test in mice (D. J. SangeR et<br>
al., EuR. J. PhaRmacol., 313, 35-42, 1996; and G. GRiebel<br>
et al., PsychophaRmacology, 146, 205-213, 1999).<br>
GRoups of 5-8 male CD1 mice, weighing 22-26 g at the time<br>
of test, weRe used. The test compounds weRe administeRed in<br>
single equimoleculaR intRapeRitoneal doses, suspended in<br>
0.25% agaR with one dRop of Tween in a volume of 10 ml/kg.<br>
ContRol  animals  Received the  vehicle  alone.  Using  an<br>
Actisystem  DAS16  (Panlab,  S.L.,  Spain)  the  cRossings<br>
(numbeR of counts) weRe RecoRded foR each mouse at 5-min<br>
inteRvals duRing a peRiod of 30 minutes afteR dosing. The<br>
inhibition peRcentage of cRossings  of  tReated animals<br>
veRsus contRol animals (the fiRst 5 min weRe discaRded) was<br>
calculated. The Results of this test aRe given in Table 3.<br><br><br><br><br>
The following non-limiting examples illustRate the scope of<br>
the pResent invention.<br>
Example 1:  N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]<br>
phenyl]-N-methyl-methanesulfonamide<br>
1.58 g (6.96 mmol) of N-(3-acetyl-phenyl)-N-methyl-<br>
methanesulfonamide weRe dissolved in 15 ml of N,N-<br>
dimethylfoRmamide dimethylacetal and the Resultant solution<br>
was Refluxed foR 18 houRs. The excess of volatile Reagent<br>
was Removed by Reduced pRessuRe distillation to yield a<br>
cRude which was chRomatogRaphied oveR silica gel using a<br>
gRadient of ethyl acetate/methanol as eluent. 1.12 g of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyi]phenyl]-N-methyl<br><br>
methanesulfonamide as a yellowish-white solid weRe obtained<br>
(yield 88.6%).<br><br>
Example 2:  N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-methyl-methanesulfonamide<br>
A mixtuRe of 0.1 g (0.93 mmol) of 4-cyano-2H-pyRazol-3-<br>
ylamine and 0.26 g (0.93 mmol) of N-[3- [3- (dimethylamino) -<br>
l-oxo-2-pRopenyl]phenyl]-N-methyl-methanesulfonamide in 10<br>
ml of glacial acetic acid was Refluxed foR 8 houRs and then<br>
the solvent was Removed by Reduced pRessuRe distillation.<br>
To  the  Resulting  Residue  weRe  added  10  ml  of<br>
dichloRomethane and 10 ml of satuRated sodium bicaRbonate<br>
solution. The two layeRs weRe sepaRated, and the aqueous<br>
layeR was washed with 10 ml of dichloRomethane. The oRganic<br>
layeRs weRe washed with 10 ml of wateR and dRied oveR<br>
magnesium sulfate. The dichloRomethane layeR was evapoRated<br>
to dRyness to yield an oil which, in the pResence of ethyl<br>
acetate,  gave  217  mg  of  N-[3-(3-cyano-pyRazolo[1,5-a]<br>
pyRimidin-7-yl)-phenyl]-N-methyl-methanesulfonamide  as  a<br>
yellow solid (yield 71%; m.p.= 193-195 °C).<br><br><br>
HPLC = 95.9%<br>
Example 3:  N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
A mixtuRe of 0.1 g (0.52 mmol) of (5-amino-lH-pyRazol-4-<br>
yl)-thiophene-2-yl-methanone and 0.146 g (0.93 mmol) of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
methanesulfonamide (obtained as descRibed in Example 2) in<br>
10 ml of glacial acetic acid was Refluxed foR 8 houRs and<br>
then  the  solvent  was  Removed  by  Reduced  pRessuRe<br>
distillation. To the Resulting Residue weRe added 10 ml of<br>
dichloRomethane and 10 ml of satuRated sodium bicaRbonate<br>
solution. The two layeRs weRe sepaRated, and the aqueous<br>
layeR was washed with 10 ml of dichloRomethane. The oRganic<br>
layeRs weRe washed with 10 ml of wateR and dRied oveR<br>
magnesium sulfate. The dichloRomethane layeR was evapoRated<br>
to dRyness to yield an oil which, in the pResence of ethyl<br>
acetate,   gave  178  mg  N-methyl-N-{3-[3-(thiophene-2-<br>
caRbonyl)-pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-methane-<br>
sulfonamide as a yellow solid (yield 83%; m.p. = 169-<br>
170°C).<br><br>
Example 4:  N- [3- [3- (dimethylamino) -l-oxo-2-pRopenyl] phenyl]-<br>
N-ethyl-methanesulfonamide<br><br>
1.1 g (4.56 mmol) of N-(3-acetyl-phenyl)-N-ethyl-<br>
methanesulfonamide weRe dissolved in 10 ml of N,N-<br>
dimethylfoRmamide dimethylacetal and the Resultant solution<br>
was Refluxed foR 18 houRs. The excess of volatile Reagent<br>
was Removed by Reduced pRessuRe distillation to yield a<br>
cRude which was chRomatogRaphied oveR silica gel using a<br>
gRadient of ethyl acetate/methanol as eluent. 1.2 g of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-<br>
methanesulfonamide as a yellowish-white solid weRe obtained<br>
(yield 88.6%)<br><br>
Example 5:  N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl) -<br>
phenyl]-N-ethyl-methanesulfonamide<br>
A mixtuRe of 0.196 g (1.82 mmol) of 4-cyano-2H-pyRazol-3-<br>
ylamine and 0.54 g (1.82 mmol) of N-[3-[3-(dimethylamino)-<br>
l-oxo-2-pRopenyl]phenyl]-N-ethyl-methanesulfonamide in  10<br>
ml of glacial acetic acid was Refluxed foR 8 houRs and then<br>
the solvent was Removed by Reduced pRessuRe distillation.<br>
To  the  Resulting  Residue  weRe  added  10  ml  of<br>
dichloRomethane and 10 ml of satuRated sodium bicaRbonate<br>
solution. The two layeRs weRe sepaRated, and the aqueous<br>
layeR was washed with 10 ml of dichloRomethane. The oRganic<br>
layeRs weRe washed with 10 ml of wateR and dRied oveR<br>
magnesium sulfate. The dichloRomethane layeR was evapoRated<br>
to dRyness to yield an oil which, in the pResence of ethyl<br>
acetate,  gave  324  mg  of  N-[3-(3-cyano-pyRazolo[1,5-<br><br>
a]pyRimidin-7-yl)-phenyl]-N-ethyl-methanesulfonamide  as  a<br>
yellow solid (yield 52.4%).<br>
1H NMR(400 MHz, CDC13) : 5  1.21 (3H, t, J= 7.2 Hz), 2.95<br>
(3H, s), 3.81 (2H, q, J= 6.8 Hz), 7.21 (1H, d, J= 4.4 Hz),<br>
7.58-7.60 (1H, m), 7.64 (1H, t, J= 7.6 Hz), 7.98 (1H, d, J=<br>
7.2 Hz), 8.06 (1H, s) , 8.41 (1H, s) ,   8.78 (1H, d, J= 4<br>
Hz) .<br>
MS (ES) m/z  = 342 (MH+)<br>
HPLC = 98.9%<br>
Example 6: N-ethyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
A  mixtuRe of 0.36 g (1.86 mmol) of 5-amino-lH-pyRazol-4-<br>
yl)-thiophene-2-yl-methanone and 0.55 g (1.86 mmol) of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-<br>
methane<br>
sulfonamide in 10 ml of glacial acetic acid was Refluxed<br>
foR 8 houRs. TheReafteR, the Reaction mixtuRe was cooled<br>
and the pRecipitate foRmed, which was filteRed, was washed<br>
fiRst with acetic acid, then with satuRated sodium<br>
bicaRbonate solution and finally with wateR. 472 mg of N-<br>
ethyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methane-sulfonamide weRe obtained<br>
as a yellow solid (yield 59.6%).<br>
lH   MMR(400 MHz, CDC13): 5  1.23 (3H, t, J= 7.6 Hz), 2.97<br>
(3H, s), 3.82 (2H, q, J= 6.8 Hz),  7.17 (1H, d, J= 4.4 Hz),<br>
7.18-7.20 (1H, m) , 7.57-7.60 (2H, m) , 7.62 (1H, t, J= 7.2<br>
Hz),   7.69 1H, dd, J= 4.8 y 1.2 Hz), 7.99-8.02 (1H, m) ,<br>
8.07-8.1 (3H, m),  8.69 (1H, s),  8.80 (1H, d, J= 4.4 Hz).<br>
MS (ES) m/z  =   427 (MH+).<br><br>
Example 7:  N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl] phenyl]-<br>
N-methyl-benzenesulfonamide<br>
1.25 g (4.32 mmol) of N-(3-acetyl-phenyl)-N-methyl-<br>
benzenesulfonamide weRe dissolved in 10 ml of N,N-<br>
dimethylfoRmamide dimethylacetal and the Resultant solution<br>
was Refluxed foR 18 houRs. The excess of volatile Reagent<br>
was Removed by Reduced pRessuRe distillation to yield a<br>
cRude which was chRomatogRaphied oveR silica gel using a<br>
gRadient of ethyl acetate/methanol as eluent. 1.25 g of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
benzenesulfonamide as a yellowish-white solid weRe obtained<br>
(yield 84%).<br>
1H NMR(400 MHz, CDC13) : α 2.92 (3H, s), 3.15 ( 3H, s), 3.19<br>
(3H, s), 5.58 (1H, d, J= 12 Hz), 7.21-7.23 (1H, m) , 7.33<br>
(1H, t, J= 8 Hz), 7.41-7.46 (2H, m) , 7.52-7.58 (4H, m) ,<br>
7.76 (1H, d, J-12 Hz),  7.77-7.80 (1H, m).<br>
HPLC = 100%<br>
Example 8:  N- [3- (3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-methyl-benzenesulfonamide<br>
A mixtuRe of 0.134 g (1.24 mmol) of 4-cyano-2H-pyRazol-3-<br>
ylamine and 0.43 g (1.24 mmol) of N-[3-[3-(dimethylamino)-<br>
l-oxo-2-pRopenyl]phenyl]-N-methyl-benzenesulfonamide in 10<br>
ml of glacial acetic acid was Refluxed foR 8 houRs and then<br>
the solvent was Removed by Reduced pRessuRe distillation.<br>
To the Resulting Residue weRe added 10 ml of<br>
dichloRomethane and 10 ml of satuRated sodium bicaRbonate<br>
solution. The two layeRs weRe sepaRated, and the aqueous<br><br>
layeR was washed with 10 ml of dichloRomethane. The oRganic<br>
layeRs weRe washed with 10 ml of wateR and dRied oveR<br>
magnesium sulfate. The dichloRomethane layeR was evapoRated<br>
to dRyness to yield an oil which, in the pResence of ethyl<br>
acetate, gave 205 mg of N-[3-(3-cyano-pyRazolo[1,5-a]<br>
pyRimidin-7-yl)-phenyl]-N-methyl-benzenesulfonamide as a<br>
yellow solid (yield 42%).<br>
1H NMR(400 MHz, CDC13) : δ  3.23 (3H, s, ) 7.13 (1H, d, J=<br>
4.8 Hz), 7.25-7.30 (1H, m) , 7.45-7.63 (6H, m) , 7.83 (1H,<br>
s), 7.93-7.97 (1H, m) ,  8.37 (1H, s), 8.75 (1H, d, J- 4.4 ,<br>
Hz) .<br>
MS (ES) m/z  = 390 (MH+)<br>
HPLC = 99.0%<br>
Example 9:  N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-benzenesulfonand.de<br>
A mixtuRe of 0.43 g (2.23 mmol) of (5-amino-lH-pyRazol-4-<br>
yl)-thiophene-2-yl-methanone and 0.8 g (2.23 mmol) of N-[3-<br>
[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
methane-sulfonamide in 10 ml of glacial acetic acid was<br>
Refluxed foR 8 houRs and then the solvent was Removed by<br>
Reduced pRessuRe distillation.  To the Resulting Residue<br>
weRe added 10 ml of dichloRomethane and 10 ml of satuRated<br>
sodium bicaRbonate solution. The two layeRs weRe sepaRated,<br>
and  the  aqueous  layeR  was  washed  with  10  ml  of<br>
dichloRomethane. The oRganic layeRs weRe washed with 10 ml<br>
of  wateR  and  dRied  oveR  magnesium  sulfate.  The<br>
dichloRomethane layeR was evapoRated to dRyness to yield an<br>
oil which, in the pResence of ethyl acetate, gave 872 g of<br>
N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br><br>
pyRimidin-7-yl]-phenyl}-benzenesulfonamide  as  a  yellow<br>
solid (yield 82.3%).<br>
XH NMR(400 MHz, CDC13) : δ 3.24 (3H, s), 7.07 (1H, d, J=<br>
4.4 Hz), 7.19 (1H, t, J= 4 Hz), 7.28-7.31 (1H, m) , 7.46-<br>
7.62 (6H, m) , 7.7 (1H, d, J= 5.2 Hz), 7.82 (1H, t, J= 2<br>
Hz), 7.97 (1H, d, J= 6.8 Hz), 8.09 (1H, d, J= 3.6 Hz), 8.66<br>
(1H, s), 8.79 (1H, d, J= 4.4 Hz). <br>
MS (ES) m/z = 475 (MH+)<br>
HPLC =97.9%<br>
Example 10:  N- [3- [3- (dimethylamino) -l-oxo-2-pRopenyl]phenyl] -<br>
N-ethyl-benzenesulfonaiRd.de<br>
1.05 g (3.46 mmol) of N-(3-acetyl-phenyl)-N-ethyl-<br>
benzenesulfonamide weRe dissolved in 10 ml of N,N-<br>
dimethylfoRmamide dimethylacetal and the Resultant solution<br>
was Refluxed foR 18 houRs. The excess of volatile Reagent<br>
was Removed by Reduced pRessuRe distillation to yield a<br>
cRude which was chRomatogRaphied oveR silica gel using a<br>
gRadient of ethyl acetate/methanol as eluent. 1.2 g of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-<br>
benzenesulfonamide as a yellowish-white solid weRe obtained<br>
(yield 96%).<br>
XH NMR(400 MHz, CDC13) : 5 1.06 (3H, t, J= 7.2 Hz), 2.92<br>
(3H, s), 3.15 ( 3H, s), 3.62 (2H, q, J= 7.6 Hz), 5.56 (1H,<br>
d, J= 12.4 Hz), 7.14-7.17 (1H, m) , 7.35 (1H, t, J= 7.6 Hz),<br>
7.42-7.49 (3H, m) , 7.52-7.60 (3H, m) , 7.76 (1H, d, J=12.4<br>
Hz) , 7.81 (1H, d, J= 8 Hz) .<br>
HPLC = 100%<br><br>
Example 11:  N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-ethyl-benzenesulfonamide<br>
A mixtuRe of 0.15 g (1.38 mmol) of 4-cyano-2H-pyRazol-3-<br>
ylamine and 0.50 g (1.38 mmol) of N-[3-[3-(dimethylamino)-<br>
l-oxo-2-pRopenyl]phenyl]-N-ethyl-benzenesulfonamide  in  10<br>
ml of glacial acetic acid was Refluxed foR 8 houRs and then<br>
the solvent was Removed by Reduced pRessuRe distillation.*<br>
To  the  Resulting  Residue  weRe  added  10  ml  of<br>
dichloRomethane and 10 ml of satuRated sodium bicaRbonate<br>
solution. The two layeRs weRe sepaRated, and the aqueous<br>
layeR was washed with 10 ml of dichloRomethane. The oRganic<br>
layeRs weRe washed with 10 ml of wateR and dRied oveR<br>
magnesium sulfate. The dichloRomethane layeR was evapoRated<br>
to dRyness to yield an oil which, in the pResence of ethyl<br>
acetate,  gave  260  mg  of  N-[3-(3-cyano-pyRazolo[1, 5-<br>
a]pyRimidin-7-yl)-phenyl]-N-ethyl-benzenesulfonamide  as  a<br>
yellow solid (yield 47%).<br>
1H NMR(400 MHz, CDC13) : 5  1.14 (3H, t, J= 6.8 Hz), 3.66<br>
(2H, q, J= 7.2 Hz), 7.12 (1H, d, J= 4.8 Hz), 7.26 (1H, d,<br>
J= 7.6 Hz), 7.46-7.65 (6H, m), 7.76 (1H, s), 8.02 (1H, d,<br>
J= 7.6 Hz), 8.38 (1H, s),  8.76 (1H, d, J= 4.4 Hz).<br>
MS (ES) m/z  = 404 (MH+)<br>
HPLC = 98.9%<br>
Exantple 12:  N-ethyi-N-{ 3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-benzenesulfonamide<br>
A mixtuRe of 0.33 g (1.70 mmol) of (5-amino-lH-pyRazol-4-<br>
yl)-thiophene-2-yl-methanone and 0.61 g (1.70 mmol) of N-<br>
[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-<br>
benzenesulfonamide in 10 ml of glacial acetic acid was<br><br>
Refluxed foR 8 houRs and then the solvent was Removed by<br>
Reduced pRessuRe distillation. To the Resulting Residue<br>
weRe added 10 ml of dichloRomethane and 10 ml of satuRated<br>
sodium bicaRbonate solution. The two layeRs weRe sepaRated,<br>
and  the  aqueous  layeR  was  washed  with  10  ml  of<br>
dichloRomethane. The oRganic layeRs weRe washed with 10 ml<br>
of  wateR  and  dRied  oveR  magnesium  sulfate.   The<br>
dichloRomethane layeR was evapoRated to dRyness- to yield an<br>
oil which, in the pResence of ethyl acetate, gave 535 mg of<br>
N-ethyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-benzenesulfonamide  as  a  yellow<br>
solid (yield 64.4%).<br>
XH NMR(400 MHz, CDCl3) : δ 1.15 (3H, t, J= 7.6 Hz) , 3.67<br>
(2H, q, J= 7.6 Hz), 7.07 (1H, d, J= 4.4 Hz), 7.18-7.21 (1H,<br>
m), 7.27-7.30 (1H, m) , 7.51 (2H, t, J= 7.6 Hz), 7.56 (1H,<br>
t, J= 7.6 Hz), 7.60-7.67 (4H, m), 7.69 (1H, dd, J= 5.2 Hz y<br>
J= 1.2 Hz), 7.75 (1H, t, J= 2 Hz), 8.06 (1H, d, J= 7.6<br>
Hz), 8.09 (1H, d, J= 3.6 Hz), 8.67 (1H, s), 8.79 (1H, d,<br>
J= 4.4 Hz).<br>
MS (ES) m/z  = 489 (MH+)<br>
HPLC = 97.9%<br>
Example 13: GeneRal pRoceduRe foR the pRepaRation of N-<br>
methyl-enamine-sulfonamides of geneRal foRmula (VI)<br>
following Scheme 2<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-<br>
ethanesulfonamide<br>
2 g (8.8 mmol) of N-(3-acetyl-phnyl)-ethanesulfonamide weRe<br>
dissolved in 15 ml of N,N-dimethylfoRmamide dimethyl acetal<br><br>
and heated at 150°C foR 12 h. The solvent was Removed by<br>
Reduced pRessuRe distillation to yield a cRude which was<br>
chRomatogRaphied (silica gel) using ethyl acetate/methanol<br>
as eluent. 1.4 g (yield= 56%) of N-[3-[3-(dimethylamino)-1-<br>
oxo-2-pRopenyl]phenyl]-ethanesulfonamide weRe obtained.<br>
0.25  g  (0.89 mmol)  of N-[3-[3-(dimethylamino)-l-oxo-2-<br>
pRopenyl]phenyl]-ethanesulfonamide weRe dissolved inn 6 ml -<br>
of dRy N,N-dimethylfoRmamide. To the solution foRmed at 0°C<br>
and undeR ineRt atmospheRe,  0.043 g (1.08 mmol)of sodium<br>
hydRide weRe added. AfteR stiRRing foR 30 minutes, 0.15 g<br>
(0.98 mmol) of ethyl iodide weRe added and stiRRing was<br>
maintained at Room tempeRatuRe foR 5 h. To the Reaction<br>
mixtuRe  1 ml of wateR and then 20 ml of 0. 5M NaOH weRe<br>
added. The pRoduct was sepaRated by extRaction with 3x25 ml<br>
of dichloRomethane, and the oRganic layeRs weRe washed with<br>
25 ml of wateR,  dRied oveR anhydRous sodium sulfate,<br>
filteRed off and evapoRated to dRyness by Reduced pRessuRe<br>
distillation.   0.25   g   (yield-   90%)   of   N-[3-[3-<br>
(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-ethane-<br>
sulfonamide weRe obtained as an oil.<br>
2H NMR (400 MHz, CDC13) : δ 1.12 (3H, t, J= 6.8 Hz), 1.37<br>
(3H, t, J= 7.6 Hz), 2.94 (3H, s), 3.01 (2H, q, J= 7.6 Hz),<br>
3.15 (3H, s), 4.79 (2H, q, J= 8.2 Hz), 5.66 (1H, d, J= 12.4<br>
Hz), 7.39-7.46 (2H, m), 7.77-7.84 (3H, m)<br>
HPLC = 99%<br>
As descRibed in the above geneRal pRoceduRe, the following<br>
compounds weRe pRepaRed:<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-ethyl-<br>
isopRopanesulfonamide<br><br><br><br><br><br><br><br>
Example 14: GeneRal pRoceduRe foR the pRepaRation of N-<br>
methyl-enamine-sulfonamides of geneRal foRmula (VII)<br>
following Scheme 3<br>
N-(3-acetylphenyl)-l-pRopane-sulfonamide<br>
1 g (7.4 mmol) of 3-aminoacetophenone weRe dissolved in 35<br>
ml of dRy dichloRomethane. To the Resultant solution cooled-<br>
at 0°C 0.89 ml (11.09 mmol) of anhydRous pyRidine and 1.26<br>
g (8.87 mmol) of 1-pRopanesulfonic acid chloRide weRe<br>
added. AfteR stiRRing the Reaction mixtuRe foR 20 h at Room<br>
tempeRatuRe and undeR ineRt atmospheRe, 15 ml of wateR weRe<br>
added. The two layeRs weRe sepaRated, and the aqueous layeR<br>
was washed with 2x15 ml of dichloRomethane. The oRganic<br>
layeRs weRe washed with 30 ml of wateR and dRied oveR<br>
anhydRous sodium sulfate. The dichloRomethane layeR was<br>
evapoRated to dRyness to yield a yellow solid, 1.8 g<br>
(yield= 100%) of N-(3-acetylphenyl)-l-pRopane-sulfonamide<br>
which was diRectly used foR the following Reaction.<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
1-pRopanesulfonamide<br>
1 g (4.14 mmol) of N-(3-acetylphenyl)-l-pRopane-sulfonamide<br>
weRe dissolved in 10 ml of N,N-dimetylfoRmamide. To the<br>
Resultant  solution  2.77  ml   (20.74  mmol)   of  N,N-<br>
dimethylfoRmamide dimethyl acetal weRe added and heated at<br>
150°C foR 2 h. The solvent was Removed by Reduced pRessuRe<br>
distillation to yield an oil, which was tReated with a<br>
mixtuRe of ethyl acetate-ethyl etheR.A small quantity of a<br>
solid pRecipitated which was discaRded The filtRate was<br>
evapoRated to dRyness,  dissolved in dichloRomethane, and<br>
the oRganic layeR was washed with 4x50 ml of wateR and<br><br><br><br>
N-(3-acetylphenyl)-2,2,2-tRifluoRoacetamide<br>
5 g (37 mmol) of 3-aminoacetophenone weRe dissolved in 30<br>
ml of anhydRous dichloRomethane. To the Resultant solution<br>
3.15 ml (38.84 mmol)   of anhydRous pyRidine and 5.5 ml<br>
(38.84 mmol) of tRifluoRoacetic anhydRide weRe added at<br>
0°C. The Reaction mixtuRe was stiRRed foR 30 minutes at the<br>
same tempeRatuRe and pouRed onto 100 ml of wateR-ice.100 ml<br>
of a satuRated solution of sodium chloRide weRe added and<br>
extRacted with 2x70 ml of dichloRomethane and 3x50 ml of •<br>
ethyl acetate. The oRganic layeRs weRe washed with wateR,<br>
dRied oveR anhydRous sodium sulfate and evapoRated to<br>
dRyness by Reduced pRessuRe distillation. 8.7 g (yield=<br>
100%)   as   a   solid   of   N-(3-acetylphenyl)-2,2,2-<br>
tRifluoRoacetamide weRe obtained.<br>
lH  NMR (400 MHz, CDC13) : 5 2.64 (3H, s), 7.53 (1H, t, J=<br>
7.6 Hz), 7.82 (1H, d, J= 7.6 Hz), 8.15 (1H, d, J= 8.2 Hz),<br>
8.25 (1H, s), 9.12 (1H, a)<br>
3-(dimetylamino)-1-[3-(methylamino)phenyl]pRop-2-en-l-one<br>
8.37 g (36.21 mmol) de N-(3-acetylphenyl)-2,2,2-tRifluoRo-<br>
acetamide weRe dissolved in 80 ml of N,N-dimetyl foRmamide.<br>
To the Resultant solution 24.23 ml (181.02 mmol) of N,N-<br>
dimethylfoRmamide dimethyl acetal weRe added and heated at<br>
150°C foR 2 h. The solvent was Removed by Reduced pRessuRe<br>
distillation to yield an oil which was tReated with 50 ml<br>
of wateR and extRact with 3x100 ml of dichloRomethane. The<br>
oRganic layeRs weRe washed with 2x200 ml of a satuRated<br>
solution of sodium chloRide, dRied oveR anhydRous sodium<br>
sulfate and evapoRated to dRyness by Reduced pRessuRe<br>
distillation. A solid was obtained, which pRecipitated fRom<br><br>
a mixtuRe of ethanol-ethyl etheR to give 4.1 g (yield= 55%)<br>
of 3-(dimethylamino)-1-[3-(methylamino)phenyl]pRop-2-en-l-<br>
one.<br>
XH NMR (400 MHz, CDC13) : δ 2.85 (3H, s), 2.87 (3H, s), 3.11<br>
(3H, s), 3.85 (1H, a), 5.68 (1H, d, J= 12.2 Hz), 6.67-6.72<br>
(1H, m) , 7.16-7.24 (3H, m), 7.77 (1H, d, J= 12.2 Hz)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-metyl-2-<br>
phenyl-ethylenesulfonamide<br>
0.4   g    (1.96   mmol)    of   3-(dimethylamino)-1-[3-<br>
(methylamino)phenyl]pRop-2-en-l-one weRe dissolved in 15 ml<br>
of dRy dichloRomethane. To the Resultant solution 0.24 ml<br>
(2.01 mmol) of anhydRous pyRidine and 0.48 g (2.37 mmol) of<br>
2-phenyl-ethene-sulfonic acid chloRide weRe added. AfteR<br>
stiRRing the Reaction mixtuRe foR 17 h at Room tempeRatuRe<br>
and undeR ineRt atmospheRe, 15 ml of wateR weRe added. The<br>
two layeRs weRe sepaRated, and the aqueous layeR was washed<br>
with 2x15 ml of dichloRomethane. The oRganic layeRs weRe<br>
washed with 30 ml of wateR and dRied oveR anhydRous sodium<br>
sulfate.  The dicholoRomethane  layeR was  evapoRated  to<br>
dRyness to yield a cRude which was chRomatogRaphied (silica<br>
gel) using dichloRomethane-methanol as eluent. 0.53 (yield=<br>
73%)   of   a   solid,   N-[3-[3-(dimethylamino)-l-oxo-2-<br>
pRopenyl]phenyl]-N-methyl-2-phenyl-ethylene-sulfonamide,<br>
weRe obtained<br>
1H NMR (400 MHz, CDCl3) :δ 2.9 (3H, a), 3.16 (3H, a), 3.31<br>
(3H, s), 5.65 (1H, d, J= 12.5 Hz), 6.7 (1H, d, J= 15.5 Hz),<br>
7.33-7.5 (8H, m), 7.77-7.85 (3H, m)<br><br>
As   descRibed   in   the   above   geneRal   pRoceduRe   the   following<br>
compounds  weRe pRepaRed:<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
3-chloRobenzenesulfonamide<br>
1H  NMR   (400  MHz,   CDC13) :  δ   2.93    (3H,   a),   3.16   (3H,   a),   3.22<br>
(3H,    s),    5.6   (1H,   d),   7.23-7.27    (1H,   m),   7.35-7.41   (3H,  -m) , -<br>
7.52-7.58    (3H,   m),   7.76   (1H,   s),   7.79-7.83   (1H,   m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
4-chloRobenzenesulfonamide<br>
1H  NMR   (400   MHz,   CDC13) :   d  2.94    (3H,   a),    3.18    (3H,   a),   3.2<br>
(3H,   a),    5.59   (1H,   d,   J=  12.2   Hz),   7.23-7.29   (1H,   m),   7.34-<br>
7.55    (6H,   m),   7.77-7.83    (2H,   m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2-chloRobenzenesulfonamide<br>
1H  NMR   (400  MHz,   CDC13) :   δ   2.73    (3H,   a),   2.96   (3H,   a),   3.24<br>
(3H,    s),    5.6   (1H,   d,   J=  12.5   Hz),   7.06-7.14    (3H,   m),   7.21-<br>
7.32    (2H,   m),   7.5-7.6   (3H,   m),   7.63   (1H,   dd),   J-  7.9  Hz,   J=<br>
1.5   Hz)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2,2,2-tRifluoRoethanesulfonamide<br>
1H NMR (400 MHz, CDC13) : 5 2.95 (3H, a), 3.18 (3H, s), 3.42<br>
(3H, s), 3.73 (2H, c, J= 9.1 Hz), 5.66 (1H, d, J= 12.2 Hz),<br>
7.42-7.53 (2H, m), 7.8 (1H, s), 7.83-7.89 (2H, m)<br><br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2,4-dichloRobenzenesulfonamide<br>
XH NMR (400 MHz, CDC13) : δ 2.96 (3H, a), 3.1ST (3H, s), 3.46<br>
(3H, s), 5.6 (1H, d, J= 12.2 Hz), 7.27 (1H, d, J= 2.1 Hz),<br>
7.31 (1H, d, J= 1.8 Hz), 7.34-7.38 (1H, m) , 7.53 (1H, d, J=<br>
2.1 Hz), 7.71-7.84 (4H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
3,4-dichloRobenzenesulfonamide<br>
XH NMR (400 MHz, CDC13) : δ 2.86 (3H, s), 3.09 (3H, s) , 3.15<br>
(3H, s), 5.52 (1H, d, J= 12.2 Hz), 7.16-7.23 (1H, m) , 7.26<br>
(1H, d, J= 2.1 Hz), 7.32 (1H, t, J= 7.9 Hz), 7.45 (1H, d,<br>
J= 8.5 Hz), 7.49 (1H, m), 7.61 (1H, d, J= 2.1 Hz)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2-cyanobenzenesulfonamide<br>
XH NMR   (400  MHz,   CDC13) :   5  2.97    (3H,   a),   3.19   (3H,   a),   3.43<br>
(3H,   s),   5.64    (1H,   d,   J=  12.2   Hz),   7.35   (1H,   m) ,   7.41    (1H,<br>
t,   J=  7.9  Hz),   7.6-7.89   (7H,   m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
3-cyanobenzenesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.94 (3H, a), 3.16 (3H, a), 3.23<br>
(3H, s), 5.62 (1H, d, J= 12.2 Hz), 7.24-7.29 (1H, m), 7.39<br>
(1H, t, J= 7.6 Hz), 7.5 (1H, m), 7.55-7.62 (1H, m) , 7.69-<br>
7.86 (5H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-M-methyl-<br>
4-cyanobenzenesulfonamide<br><br>
XH NMR   (400  MHz,   CDC13) :   5  2.94    (3H,   a),   3.17   (3H,   a),   3.22<br>
(3H,   s),   5.6   (1H,   d,   J=  12.2  Hz),   7.24-7.3   (1H,   m),   7.39<br>
(1H,   t,   J=  7.9  Hz),   7.51   (1H,   m) ,   7.64-7.7   (2H,   m),   7.73-<br>
7.82    (4H,   m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
3-nitRobenzenesulfonamide<br>
lH NMR   (400   MHz,   CDC13) :  δ   2.93    (3H,   a),    3.16   (3H,   a),    3.26<br>
(3H,   s),   5.6   (1H,   d,   J=  12.2  Hz),   7.27-7.32   (2H,   m),   7.39<br>
(1H,   t,   J=  7.9  Hz),    7.48   (1H,   m) ,   7.62-7.82    (4H,   m),   8.4-<br>
8.44    (1H,   m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
4-nitRobenzenesulfonamide<br>
2H NMR (400 MHz, CDC13) : 5 2.92 (3H, a), 3.17 (3H, a), 3.25<br>
(3H, s), 5.6 (1H, d, J= 12.5 Hz), 7.25-7.29 (1H, m), 7.39<br>
(1H, t, J= 7.9 Hz), 7.53 (1H, m) , 7.73 (2H, d, J= 9 Hz),<br>
8.4-8.44 (1H, m), 7.77-7.84 (2H, m), 8.3 (2H, d, J= 9 Hz)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2-thiophenesulfonamide<br>
XH  NMR (400 MHz, CDCI3) : δ 2.85 (3H, a), 3.07 (3H, a), 3.19<br>
(3H, s), 5.54 (1H, d, J= 12.5 Hz), 6.99 (1H, dd, J= 4.8<br>
Hz), 7.19-7.32 (3H, m) , 7.48-7.53 (2H, m) , 7.67-7.74 (2H,<br>
m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
5-methyl-4-isoxazolesulfonamide<br><br>
*H NMR (400 MHz, CDC13) : 5 2.13 (3H, s) , 2.88 (3H, a), 3.11<br>
(3H, s), 3.19 (3H, m) , 5.53 (1H, d, J= 12.5 Hz), 7.21-7.28<br>
(1H, m) , 7.35 (1H, t, J= 7.9 Hz), 7.56-7.81 (3H, Rn) , 8.15<br>
(1H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2-tRifluoRomethyl-5-methyl-3-fuRansulfonamide<br>
*H NMR (400 MHz, CDCI3) : δ 2.13 (3H, s) , 2.94 (3H, a), 3.27<br>
(3H, s), 5.61 (1H, d, J= 12.2 Hz), 6.8 (1H, m), 7.3-7.44<br>
(2H, m), 7.66 (1H, t), 7.79-7.86 (2H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
6- (RnoRpholin-4-yl) -3-pyRidinesulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 2.88 (3H, a), 3.13 (3H, s),<br>
3.54-3.58 (4H, m) , 3.71-3.75 (4H, m), 5.59 (1H, d, J= 12.5<br>
Hz), 6.43 (1H, dd, J= 9.1 Hz), 7.21-7.3 (2H, m), 7.35 (1H,<br>
dd, J= 9.1 Hz), 7.58-7.6 (1H, m), 7.69-7.74 (2H, m), 8.3<br>
(1H, dd, J= 2.6 y 0.8 Hz)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
2,4-dimethyl-5-thiazolesulfonamide<br>
XH NMR (400 MHz, CDC13) : δ 2.06 (3H, s) , 2.6 (3H, s) , 2.88<br>
(3H, a), 3.1 (3H, a), 3.23 (3H, s), 5.56 (1H, dd, J= 12.2<br>
Hz), 7.23-7.38 (2H, m), 7.7-7.8 (3H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
cyclopRopanesulfonamide<br>
lH  NMR (400 MHz, CDC13) : 5 1.03-1.12 (1H, m) , 1.23-1.32<br>
(1H, m), 1.5-1.54 (1H, m), 2.26-2.37 (1H, m), 2.88 (3H, a),<br><br>
3.09 (3H, a), 3.16-3.28 (1H, m) , 3.31 (3H, s) , 5.62 (1H, d,<br>
J= 12.2 Hz), 7.3-7.37 (1H, m) , 7.44-7.48 (1H, m) , 7.7-7.77<br>
(2H, m), 7.87-7.88 (1H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
benzylsulfonamide<br>
lH  NMR (400 MHz, CDC13)-: 5 3.05 (3H, a), 3.25 (6H, s) , 4.37<br>
(2H, s), 5.76 (1H, d, J= 12.2 Hz), 7.44-7.51 (7H, m), 7.83-<br>
7.93 (3H, m)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl-<br>
vinylsulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.92 (3H, a), 3.14 (3H, a), 5.66<br>
(1H, d, J= 12.2 Hz), 5.97 (1H, dd), 6.13 (1H, dd), 6.39<br>
(1H, dd) , 7.31-7.47 (2H, m), 7.7-7.75 (2H, m), 7.87 (1H, d,<br>
J= 12.2 Hz)<br>
N-[3-[3-(dimethylamino)-l-oxo-2-pRopenyl]phenyl]-N-methyl<br>
3,5-dimethyl-4-isoxazolesulfonamide<br>
XH  NMR   (400   MHz,   CDC13) :   5   2.03    (3H,   s) ,   2.27    (3H,   s) ,   2.94<br>
(3H,   a),   3.16   (3H,   a),   3.27   (3H,   s),   5.58    (1H,   d,   J=   12.2<br>
Hz),   7.31-7.43   (2H,   m),   7.66   (1H,   m),   7.77-7.85   (2H,   m)<br>
N- [3- [3- (dimethylamino) -l-oxo-2-pRopenyl] phenyl] -N-methyl<br>
1,3,5-tRimethyl-4-pyRazolesulfonamide<br>
XH NMR (400 MHz, CDC13) : δ 1.96 (3H, s) , 2.84 (3H, a), 3.16<br>
(3H, a), 3.2 (3H, a), 3.68 (3H, s) , 5.63 (1H, d, J= 12.5<br>
Kz), 7.34-7.37 (2H, m), 7.63 (1H, m), 7.76-7.82 (2H, m)<br><br>
Example 16: GeneRal pRoceduRe foR the pRepaRation of<br>
pyRazolo[l,5-a]pyRimidines of geneRal foRmula (I) following<br>
Scheme 1<br>
N-pRop-2-inyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-<br>
a] pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
0.1 g (0.33 mmol) of 4-thiophene-2-caRbonyl-2H-pyRazol-3-<br>
ylamine and 0.063 g (0.33 mmol) of N-[3-[3-(dimethylamino)-<br>
l-oxo-2-pRopenyl]phenyl]-N-pRop-2-inyl-methanesulfonamide<br>
weRe dissolved in 10 ml of glacial acetic acid. AfteR<br>
Refluxing foR 8 houRs, the solvent was Removed by Reduced<br>
pRessuRe distillation. To the Resultant Residue 10 ml of<br>
dichloRomethane and 10 ml of a satuRated solution of sodium<br>
bicaRbonate.weRe added. The two layeRs weRe sepaRated, and<br>
the aqueous layeR was washed with 10 ml of dichloRomethane.<br>
The oRganic layeRs weRe washed with 10 ml of wateR and<br>
dRied oveR magnesium sulfate. The dichloRomethane layeR was<br>
evapoRate to dRyness to yield an oil which, in the pResence<br>
of ethyl acetate gave a yellow solid, 111 mg (yield= 78%)<br>
N-pRop-2-inyl-N-{3-[3-(thiophene-2-caRbonyl)-pyRazolo[1,5-<br>
a]pyRimidin-7-yl]-phenyl}-methanesulfonamide.<br><br><br>
As descRibed in the geneRal pRoceduRe of Example 16, the<br>
following exemplified compounds weRe pRepaRed:<br>
Example 17: N-pRopyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : δ 0.94 (3H, t, J= 7.6 Hz), 1.42<br>
(3H,t, J= 7.6 Hz),- 1.54-1.63 (2H, m) ,' 3.08-3.31 (2H, m),<br>
3.75 (2H, t, J= 7.2 Hz), 7.16 (1H, d, J= 4.4 Hz), 7.19-7.21<br>
(1H, m) , 7.59-7.65 (2H, m), 7.69-7.71 (1H, m) , 7.99-8.02<br>
(1H, m) .8.09-8.11 (2H, m, J= 2 Hz).8.71 (1H, s).8.82 (1H,<br>
d, J= 4.4 Hz)<br>
MS (ES) m/z -  455 (MH+)<br>
HPLC = 97.8 6%<br>
Example 18: N-ethyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
ZH NMR (400 MHz, CDC13) : δ 1.22 (3H, t, J= 6.8 Hz), 1.43<br>
(3H, t, J= 7.6 Hz), 3.11 (2H, c, J= 7.6 Hz), 3.85 (2H, c,<br>
J= 6.8 Hz), 7.16 (1H, d, J= 4.4 Hz), 7.19-7.21 (1H, m, J=<br>
4.4 Hz), 7.58-7.66 (2H, m), 7.69-7.71 (1H, m), 7.99-8.02<br>
(1H, m) , 8.09-8.11 (2H, m).8.71 (1H, s).8.82 (1H, d, J= 4.4<br>
Hz)<br>
MS (ES) m/z = 441 (MH+)<br>
HPLC = 97.73%<br>
Example 19: N-pRop-2-inyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-ylJ-phenyl}-2-pRopanesulfonamide<br>
2H NMR (400 MHz, CDC13) : δ 1.44 (6H, d, J= 6.4 Hz), 2.42<br>
(1H, m) , 3.44-3.51 (1H, m) , 4.56 (1H, s), 7.15 (1H, d, J= 4<br><br>
Hz), 7.19-7.20 (1H, m), 7.65 (1H, t, J= 8 Hz), 7.69-7.71<br>
(1H, m) , 7.76-7.79 (1H, m), 8.02-8.05 (1H, m).8.09-8.11<br>
(1H, m).8.24-8.25 (1H, m).8.7 (1H, s).8.82 (1H, d, J= 4.4<br>
Hz)<br>
MS (ES) m/z = 465 (MH+)<br>
HPLC = 100%<br>
Example 20: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.41 (3H, t, J= 7.2 Hz), 3.12<br>
(2H, c, J= 7.6 Hz), 3.45 (3H, s), 7.15 (1H, d, J= 4.4 Hz),<br>
7.19-7.23 (1H, m, J= 4.4 Hz), 7.61-7.63 (2H, m) , 7.69-7.71<br>
(1H, m) , 7.92-7.95 (1H, m) , 8.09-8.11 (1H, m) , 8.13-8.14<br>
(1H, m).8.71 (1H, s).8.82 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 427 (MH+)<br>
HPLC = 84.2%<br>
Example 21: N-butyl-N-{3-[3-(thiophene-2-caRbonyl) -<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDCI3) : δ 0.91 (3H, t, J= 7.2 Hz), 1.36-<br>
1.44 (5H, m), 1.52-1.57 (2H, m), 3.1 (2H, c, J= 7.6 Hz),<br>
3.78 (2H, t, J= 7.2 Hz), 7.16 (1H, d, J= 4.4 Hz), 7.20-7.25<br>
(1H, m), 7.61-7.63 (2H, m), 7.69-7.71 (1H, m) , 7.99-8.02<br>
(1H, m).8.09-8.11 (2H, m).8.71 (1H, s).8.32 (1H, d, J= 4.4<br>
Hz)<br>
MS (ES) m/z = 469 (MH+)<br>
HPLC = 99.06%<br>
Example 22: 7-(3-(2-isothiazolidinyl-l,1-dioxide)-phenyl)-<br>
3-(thiophene-2-caRbonyl)-pyRazolo[1,5-a]pyRimidine<br><br>
XH NMR (400 MHz, CDC13) : δ 2.57-2.61 (2H, m) , 3.43 (2H, t,<br>
J= 7.6 Hz), 3.87 (2H, t, J= 6.4 Hz), 7.14 (1H, d, J= 4 Hz),<br>
7.19 (1H, t), 7.46-7.50 (1H, m), 7.58 (1H, t), 7.68-7.69<br>
(1H, d, J= 4 Hz), 7.78-7.79 (1H, d) , 7.9 (1H, s).8.09 (1H,<br>
d, J= 3.2 Hz).8.69 (1H, s).8.79 (1H, d, J= 4.4  Hz)<br>
MS (ES) m/z = 425 (MH+)<br>
HPLC =•97.1%<br>
Example 23: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1, 5-a]pyRimidin-7-yl]-phenyl}-2-pRopane-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.4 (6H, d, J= 6.8 Hz), 3.36-<br>
3.41 (1H, m) , 3.47 (3H, s), 7.15 (1H, d, J= 4.4 Hz), 7.18-<br>
7.21 (1H, m), 7.58-7.64 (2H, m) , 7.69-7.71 (1H, m), 7.89-<br>
7.93 (1H, m), 8.09-8.10 (1H, m) , 8.14-8.16 (1H, m) .8.7 (1H,<br>
s) .8.81 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 441 (MH+)<br>
HPLC = 96.35%<br>
Example 24: N-ethyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1, 5-a]pyRimidin-7-yl]-phenyl}-2-pRopane-<br>
sulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 1.21 (3H, t, J= 6.8 Hz), 1.41<br>
(6H, d, J= 6.4   Hz), 3.28-3.32 (1H, m), 3.37 (2H, c, J= 7.2<br>
Hz), 7.16 (1H, d, J= 4.4 Hz), 7.18-7.21 (1H, m) , 7.61-7.62<br>
(2H, Ra), 7.69-7.71 (1H, m) , 7.9-8.1 (1H, m) , 8.09-8.12 (1H,<br>
m).8.7 (1H, s).8.81 (1H, d, J= 4.4 Hz).<br>
MS (ES) m/z = 455 (MH+)<br>
HPLC = 88.35%<br><br>
Example 25: N-pRopyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2-pRopane-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 0.93 (3H, t, J= 7.2 Hz), 1.41<br>
(6H, d, J= 6.8 Hz), 1.57 (2H, q, J= 7.2 Hz), 3.3 (1H, m, J=<br>
6.8 Hz), 3.77 (2H, t, J= 7.2 Hz), 7.16 (1H, d, J= 4.4 Hz),<br>
7.19-7.21 (1H, m) , 7.61-7.63 (2H, m) , 7.69-7.71 (1H, m) ,<br>
7.99-8.11 (1H, m), 8.09-8.13 (2H, m), 8.7 (1H, s), 8.81<br>
(1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 469 (MH+)<br>
HPLC = 97%<br>
Example 26: N-butyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2-pRopane-<br>
sulfonamide<br>
*H NMR (400 MHz, CDC13) : 5 0.9 (3H, t, J= 7.2 Hz), 1.36<br>
(2H, q, J= 3 Hz), 1.41 (6H, d, J= 6.8 Hz), 1.51-1.55 (2H,<br>
m), 3.29 (1H, m, J= 6.4 Hz), 8.81 (2H, t, J= 6.8 Hz), 7.16<br>
(1H, d, J= 4.4 Hz), 7.19-7.21 (1H, m) , 7.62-7.63 (2H, m),<br>
7.70-7.71 (1H, m), 7.99-8.01 (1H, m), 8.10-8.14 (2H, m) ,<br>
8.7 (1H, s), 8.82 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 483 (MH+)<br>
HPLC = 100%<br>
Example 27: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-pRop-2-inyl-methanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.53 (1, s) , 3.1 (3H, s),   4.53<br>
(2H, s), 7.19 (1H, d, J= 4.4 Hz), 7.65 (1H, t, J= 7.6 Hz),<br>
7.85-7.88 (1H, m, J= 4.4 Hz), 8.0-8.29 (1H, m), 8.27-8.23<br>
(1H, m), 8.42 (1H, s), 8.79 (1H, d, J= 4.4 Hz)<br><br>
MS (ES) m/z = 352 (MH+)<br>
HPLC = 95.78%<br>
Example 28: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-pRopyl-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 0.93 (3H, t, J= 7.6 Hz), 1.41<br>
(3H, t, J= 7.2 Hz), 1.54-1.59 (2H, m), 3.01 (2H, q, J= 7.2<br>
Hz), 3.74 (2H, t, J= 7.2 Hz), 7.2 (1H, d, J= 4.4 Hz), 7.59-<br>
7.65 (2H, m) , 7.96-7.99 (1H, m), '8 . 07-8.08 (1H, m), 8.41<br>
(1H, s), 8.78 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 370 (MH+)<br>
HPLC = 98%<br>
Example 29: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]~N-ethyl-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.21 (3H, t, J= 7.2 Hz), 1.42<br>
(3H, t, J= 7.6 Hz), 3.09 (2H, q, J- 7.6 Hz), 3.84 (2H, q,<br>
J= 7.2 Hz), 7.2 (1H, d, J= 4 Hz), 7.58-7.65 (2H, m), 7.97-<br>
7.99 (1H, m) , 8.07 (1H, t, J= 1.6 Hz), 8.42 (1H, s), 8.78<br>
(1H, d, J= 4.8 Hz)<br>
MS (ES) m/z = 356 (MH+)<br>
HPLC = 99%<br>
Example 30: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-pRop-2-inyl-pRopane-2-sulfonamide<br>
lR  NMR (400 MHz, CDC13) : 5 1.43 (6H, d, J= 7.2 Hz), 2.41-<br>
2.42 (1H, m), 3.43-3.50 (1H, m),   3.54 (2H, s), 7.2 (1H, d,<br>
J= 4 Hz), 7,63 (1H, t, J= 7.6 Hz), 7.77-7.80 (1H, m), 7.99-<br>
8.02 (1H, m) , 8.21-8.22 (1H, m) , 8.42 (1H, s).8.78 (1H, d,<br>
J= 4.4 Hz)<br><br>
MS (ES) m/z = 380 (MH+)<br>
HPLC = 97.4 6%<br>
Example 31: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl] -N-methyl-ethanesulf onamide<br>
XH NMR (400 MHz, CDC13) : 5 1.4 
(2H, q, J= 7.2 Hz), 3.43 (3H, s) , 7.19 (1H, d, J= 4.4 Hz) &gt;<br>
7.60-7.63 (2H, m), 7.89-7.92 (1H, m), 8.11 (1H, a), 8.42<br>
(1H, s), 8.78 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 342 (MH+)<br>
HPLC = -91%<br>
Example 32: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-butyl-ethanesulfonamide<br>
XH NMR (400  MHz, CDC13) : 5 1.43 (3H, t, J= 7.2 Hz), 2.49<br>
(1H, t, J= 2.4 Hz), 3.26 (2H, q, J= 7.2 Hz), 4.54 (2H, d,<br>
J= 2.4 Hz), 7.2 (1H, d, J= 4 Hz), 7.64 (1H, t, J= 8 Hz),<br>
7.82-7.85 (1H, m) , 8.00-8.03 (1H, m), 8.25 (1H, t, J= 2<br>
Hz), 8.42 (1H, s), 8.79 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 366 (MH+)<br>
HPLC = 98%<br>
Example 33: 7-(3-(2-isothiazolidinyl-l,1-dioxide)-phenyl)-3-<br>
cyano-pyRazolo[1,5-a]pyRimidine<br>
1H   NMR (4 00 MKz, DMSO-d6) : 5 2.4 7-2.51 (2H, m) , 3.61 (2H,<br>
t, J= 7.6 Hz), 3.87 (2H, t, J= 6.8 Hz), 7.52-7.56 (1H, m),<br>
7.6 (1H, d, J= 4.8  Hz), 7.66 (1H, t), 7.8-7.85 (2H, m),<br>
3.88 (1H, s), 8.95 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 340 (MH+)<br>
HPLC = 91.47%<br><br>
Example 34: N-[3-(3-cyano-pyRazolo[1, 5-a]pyRimidin-7-yl)-<br>
phenyl]-N-methyl-2-pRopanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.39 (6H, d, J= 6.8 Hz), 3.38<br>
(1H, m), 3.45 (3H, s), 7.19 (1H, d, J= 4 Hz), 7.56-7.66<br>
(2H, m), 7.87-7.90 (1H, m) , 8.125 (1H, t, J= 2 Hz), 8.41<br>
(1H, s), 8.78 (1H, d, J= 4 Hz)<br>
MS (ES) m/z = 356 (MH+)<br>
HPLC = 91%<br>
Example 35: N-[3-(3-cyano-pyRazolo[1, 5-a]pyRimidin-7-yl)-<br>
phenyl]-N-ethyl-2-pRopanesulfonamide<br>
2H NMR (400 MHz, CDCI3) : 5 1.95 (3H, t, J= 7.2 Hz), 1.41<br>
(6H, d, J= 6.8 Hz), 3.28 (1H, m), 3.86 (2H, q, J= 7.2 Hz),<br>
7.2 (1H, d, J= 4.4 Hz), 7.61-7.62 (2H, m), 7.96-7.99 (1H,<br>
m), 8.08-8.09 (1H, m), 8.41 (1H, s), 8.78 (1H, d, J= 4 Hz)<br>
MS (ES) m/z = 370 (MH+)<br>
HPLC = 98%<br>
Example 36: N-[3-(3-cyano-pyRazolo[1, 5-a]pyRimidin-7-yl)-<br>
phenyl]-N-butyl-2-pRopanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 0.89 (3H, t, J= 7.2 Hz), 1.32-<br>
1.36 (2H, m), 1.53-1.56 (6H, d, J= 6.8 Hz), 1.49-1.51 (2H,<br>
m), 3.27 (1H, m), 3.79 (2H, t, J= 7.6 Hz), 7.2 (1H, d, J=<br>
4.4 Hz), 7.61-7.63 (2H, m) , 7.95-7.93 (1H, m), 8.1 (1H, a),<br>
8.41 (1H, s), 8.78 (1H, d, J= 4 Hz)<br>
MS (ES) m/z = 398 (MH+)<br>
HPLC = 95%<br><br>
Example 37: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N-pRopyl-2-pRopanesulfonamide<br>
aH NMR (400 MHz, CDC13) : 5 0.92 (3H, t, J= 7.2 Hz), 1.4<br>
(6H, d, J= 6.8 Hz), 1.53-1.56 (2H, m), 3.27 (1H, m), 3.76<br>
(2H, t, J= 7.6 Hz), 7.2 (1H, d, J= 4.4 Hz), 7.61-7.63 (2H,<br>
m), 7.96-7.98 (1H, Ra), 8.1 (1H, a), 8.41 (1H, s), 8.78 (1H,<br>
d, J= 4 Hz)<br>
MS (ES) m/z = 384 (MH+)<br>
HPLC = 98.05%<br>
Example 38: N-[3-(3-cyano-pyRazolo[1,5-a]pyRimidin-7-yl)-<br>
phenyl]-N~pRop-2-inyl-ethanesulfonamide<br>
*H NMR (400 MHz, CDCl3) : 5 7.2 (3H, t, J= 7.6 Hz), 2.48<br>
(1H, s), 3.25 (2H, c, J= 7.2 Hz), 4.54 (2H, s), 7.2 (1H, d,<br>
J= 4 Hz), 7.64 (1H, t, J= 8.4 Hz), 7.82-7.85 (1H, m) , 7.99-<br>
8.03 (1H, m), 8.26-8.26 (1H, m), 8.42 (1H, s).8.79 (1H, d,<br>
J= 4.1 Hz)<br>
MS (ES) m/z = 366 (MH+)<br>
HPLC =97.7%<br>
Example 39: N-methyl-N-{3-[3-(pyRidin-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.92 (3H, s) , 3.41 (3H, s) , 7.17<br>
(1H, d, J= 4.4 Hz), 7.48-7.51 (1H, m) , 7.62-7.63 (2H, m),<br>
7.90-7.94 (2H, m), 3.16-8.16 (1H, m), 8.24 (1H, d, J= 6.8<br>
Hz), 8.73-8.75 (1H, m) , 8.90 (1H, d, J= 4.4 Hz), 9.36 (1H,<br>
s)<br>
MS (ES) m/z = 408 (MH+)<br>
HPLC = 99%<br><br>
Example 40: N-ethyl-N-{3-[3-(pyRidin-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl] -phenyl}-methanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.22 (3H, t, J= 7.2 Hz), 2.97<br>
(3H, s), 3.82 (2H, q, J= 7.2 Hz), 7.18 (1H, d, J= 4 Hz),<br>
7.48-7.51 (1H, m), 7.59-7.67 (2H, m) , 7.90-7.94 (1H, m),<br>
7.98-8.00 (1H, m), 8.15 (1H, s), 8.24 (1H, d, J= 7.6 Hz),<br>
■8.75 (1H, d, J= 4.8 Hz), 8.9 (1H, d, J= 4.4 Hz), 9.36 (1H,<br>
s)<br>
MS (ES) m/z = 422 (MH+)<br>
HPLC = 100%<br>
Example   41:   N-pRop-2-inyl-N-{3-[3-(pyRidin-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
XH NMR (400 MHz, CDC13): 5 2.52-2.53 (1H, m), 3.12 (3H, s),<br>
4.53-4.54 (2H, m), 7.17 (1H, d, J= 4.4 Hz), 7.48-7.52 (1H,<br>
m), 7.65 (2H, t, J= 8 Hz), 7.82-7.85 (1H, m), 7.92 (1H, t,<br>
J= 0.8 Hz), 8.03-8.06 (1H, m) , 8.24 (1H, d, J= 8.4 Hz),<br>
8.35 (1H, s), 8.75 (1H, d, J= 5.6 Hz), 8.9 (1H, d, J= 5.6<br>
Hz), 9.37 (1H, s)<br>
MS (ES) m/z = 432 (MH+)<br>
HPLC = 96%<br>
Example 42: N-methyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDCI3): 5 1.4 (3H, t, J= 7.6 Hz), 3.12<br>
(2H, q, J= 7.6 Hz), 3.44 (3H, s), 7.17 (1H, d, J= 4.4 Hz),<br>
7.48-7.51 (1H, m), 7.61-7.64 (2H, m) , 7.88-7.93 (2H, m),<br>
8.16 (1H, t, J= 2 Hz), 8.24 (1H, d, J= 8.4 Hz), 8.74-8.75<br>
(1H, m) , 8.89 (1H, d, J= 5.2 Hz), 9.36 (1H, s)<br>
MS (ES) m/z = 422 (MH+)<br><br>
Example 43: N-ethyl-N-{3-[3-(pyRidin-2-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
lH  NMR (400 MHz, CDC13) : 5 1.35 (3H, t, J= 7.2 Hz), 1.33<br>
(3H, t, J=» 7.2 Hz), 3.05 (2H, q, J= 7.2 Hz), 3.77 (2H, q,<br>
J= 7.2 Hz), 7.14 (1H, d, J= 4.8 Hz), 7.40-7.43 (1H, m),<br>
7.54-7.56 (2H, m) , 7.82-7.85 (1H, m) , 7.92-7.93 (1H, m),<br>
8.1 (1H, s), 8.13 (1H, d, J= 8 Hz), 8.66 (1H, d, J= 4.4<br>
Hz), 8.81 (1H, d, J= 4.4 Hz), 9.28 (1H, s)<br>
MS (ES) m/z = 436 (MH+)<br>
HPLC = 95%<br>
Example 44: N-pRop-2-inyl-N-{3-[3-(pyRidin-2~caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.42 (3H, t, J= 7.2 Hz), 2.47<br>
(1H, ), 3.26 (2H, q, J= 7.2 Hz), 4.54 (2H, d, J= 2.4 Hz),<br>
7.17 (1H, d, J= 4.8 Hz), 7.48-7.51 (1H, m), 7.63 (1H, t, J=<br>
7.6 Hz, 7.8-7.82 (1H, m) , 7.89-7.93 (1H, m), 8.02-8.05 (1H,<br>
m), 8.23 (1H, d, J= 8 Hz), 8.3 (1H, t, J= 2 Hz), 8.73-8.75<br>
(1H, m), 8.89 (1H, d, J= 5.2 Hz), 9.36 (1H, s)<br>
MS (ES) m/z = 446 (MH+)<br>
HPLC = 98%<br>
Example 45: N-methyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
lH  NMR (400 MHz, CDC13) : 5 2.92 (3H, s) , 3.41 (3H, s) , 7.2<br>
(1H, d, J= 4.4 Hz), 7.26-7.64 (2H, m) , 7.71-7.73 (2H, m),<br>
7.93-7.96 (1H, m) , 8.127-8.129 (1H, m), 8.57 (1H, s), 8.81-<br>
8.83 (3H, m)<br><br>
MS (ES) m/z = 408 (MH+)<br>
HPLC = 95%<br>
Example 46: N-ethyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.22 (3H, t, J= 7.2 Hz), 2.96<br>
(3H, s), 3.82 (2H, q, J= 7.2 Hz), 7.22 (1H, d, J= 4.4 Hz),<br>
(1H, m) , 5.73 (2H, d, J= 5.6 Hz), 8.01 (1H, d, J= 7.6 Hz),<br>
8.1 (1H, t, J= 2 Hz), 8.57 (1H, s), 8.82-8.84 (3H, m)<br>
MS (ES) m/z = 422 (MH+)<br>
HPLC = 89%<br>
Example 47: N-methyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo<br>
[1, 5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
*H NMR (400 MHz, CDC13) : 5 1.39 (3H, t, J= 7.2 Hz), 3.11<br>
(2H, q, J= 7.2 Hz), 3.44 (3H, s), 7.2 (1H, d, J= 4.8 Hz),<br>
7.62-7.63 (2H, m) , 7.71-7.72 (2H, m), 7.92-7.94 (1H, m),<br>
8.13-8.14 (1H, m), 8.57 (1H, s), 8.81-8.83 (3H, m)<br>
MS (ES) m/z = 422 (MH+)<br>
HPLC = 94%<br>
Example 48: N-ethyl-N-{3-[3-(pyRidin-4-caRbonyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
lR  NMR (400 MHz, CDC13) : 5 1.13 (3H, t, J= 7.2 Hz), 1.318<br>
(3H, t, J= 7.2 Hz), 3.04 (2H, q, J= 7.2 Hz), 3.77 (2H, q,<br>
J= 7.2 Hz), 7.18 (1H, d, J= 4.8 Hz), 7.52-7.58 (2H, m) ,<br>
7.61-7.94 (2H, m), 8.05 (1H, s), 8.47 (1H, s) , 8.71-8.73<br>
(3H, m)<br>
MS (ES) m/z = 436 (MH+)<br>
HPLC = 89%<br><br>
Example 49: N-pRop-2-inyl-N-{3-[3-(pyRidin-4-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
lH NMR (400 MHz, CDC13) : 5 1.22 (3H, t, J= 7.2 Hz), 2.96<br>
(3H, s), 3.82 (2H, q, J= 7.2 Hz), 7.22 (1H, d, J= 4.4 Hz),<br>
7.58-7.60 (1H, m), 7.66 (1H, t, J= 8 Hz), 7.71-7.73 (2H,<br>
m), 8.01 (1H, d, J= 7.6 Hz), 8.1 (1H, t, J= 2 Hz), 8.57<br>
(1H, s), 8.82-8.84 (3H, m)<br>
MS (ES) m/z = 422 (MH+)<br>
HPLC =8 9%<br>
Example 50: N-pRop-2-inyl-N-{3-[3-(pyRidin-4-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 2.53 (1H, t, J= 2 Hz), 3.11 (3H,<br>
s), 4.54 (2H, d, J= 2.4 Hz), 7.2 (1H, d, J= 4.4 Hz), 7.66<br>
(1H, t, J= 7.6 Hz), 7.72-7.73 (2H, m) , 7.86-7.89 (1H, m),<br>
8.03-8.05 (1H , m), 8.31 (1H, t, J= 2 Hz), 8.56 (1H, s),<br>
8.82-8.84 (3H, m)<br>
MS (ES) m/z = 432 (MH+)<br>
HPLC = 93%<br>
Example 51: N-methyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-<br>
pyRazolo[1,5-a JpyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
lH  NMR (400 MHz, CDC13) : 5 2.93 (3H, s) , 3.42 (3H, s),<br>
7.15-7.20 (3H, m), 7.61-7.63 (2H, m), 7.94-7.99 (3H, m),<br>
8.12-8.13 (1H, m), 8.55 (1H, s), 8.78 (IK, d, J= 4.4 Hz)<br>
MS (ES) m/z = 425 (MH+)<br>
HPLC = 98%<br>
Example 52: N-ethyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br><br>
XH NMR (400 MHz, CDC13) : 5 1.23 (3H, t, J= 7.2 Hz), 2.97<br>
(3H, s), 3.82 (2H, q, J= 7.2 Hz), 7.16-7.20 (3H, m), 7.56-<br>
7.60	(1H, m), 7.65 (1H, t, J= 8 Hz), 7.96-8.02 (3H, m) , 8.1<br>
(1H, t, J= 2 Hz), 8.55 (1H, s), 8.79 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 439 (MH+)<br>
HPLC = 98%<br>
Example 53: N-methyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
2H NMR (400 MHz, CDC13) : 5 1.38 (3H, t, J= 7.2 Hz), 3.11<br>
(2H, q, J= 7.2 Hz), 3.42 (3H, s), 7.13-7.17 (3H, m), 7.59-<br>
7.61	(2H, m), 7.90-7.97 (3H, m, J= 8 Hz), 8.13 (IB, a),<br>
8.53 (1H, s), 8.76 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 439 (MH+)<br>
HPLC = 94%<br>
Example 54: N-ethyl-N-{3-[3-(fluoRobenzene-4-caRbonyl)-<br>
pyRazolo [1, 5-a]pyRimidin-7-yl] -phenyl }-ethanesulfonaniide<br>
*H NMR (400 MHz, CDC13) : 5 1.21 (3H, t, J= 7.2 Hz), 1.41<br>
(3H, t, J= 7.2 Hz), 3.1 (2H, q, J« 7.2 Hz), 3.84 (2H, q, J=<br>
7.2 Hz), 7.14-7.18 (3H, m), 7.58 (2H, m), 7.94-8.01 (3H,<br>
m) , 8.1 (1H, a), 8.54 (1H, s), 8.77 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 453 (MH+)<br>
HPLC = 99%<br>
Example 55: N-pRop-2-inyl-N-{3-[3-(fluoRobenzene-4-<br>
caRbonyl)-pyRazolo[1/5-a]pyRimidin-7-yl]-phenyl}-<br>
ethanesulfonamide<br>
aH NMR (400 MHz, CDC13): 6 1.43 (3H, t, J= 7.2 Hz), 2.48<br>
(1H, t, J= 2.4 Hz), 3.27 (2H, q, J= 7.2 Hz), 4.54 (2H, d,<br><br>
J= 2.4 Hz), 7.15-7.2 (3H, m), 7.64 (1H, t, J= 8 Hz), 7.81-<br>
7.84 (1H, m), 7.96-8.04 (3H, m), 8.28 (1H, a), 8.56 (1H,<br>
s) , 8.79 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 463 (MH+)<br>
HPLC = 96%<br>
Example 56: N-pRop-2-inyl-N-{3-[3-(fluoRobenzene-4-<br>
caRbonyl)-pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-<br>
methanesulfonamide<br>
XH NMR (400 MHz, CDCl3) : 5 2.54 (1H, t, J= 2 Hz), 3.1 (3H,<br>
s), 4.52 (2H, d, J= 2 Hz), 7.14-7.18 (3H, m), 7.64 (1H, t,<br>
J= 7.6 Hz), 7.83-7.86 (1H, m) , 7.94-7.96 (2H, m) , 8.02-8.04<br>
(1H, m), 8.3 (1H, t, J= 2 Hz), 8.54 (1H, s), 8.77 (1H, d,<br>
J= 4 Hz)<br>
MS (ES) m/z = 4 49 (MH+)<br>
HPLC = 96%<br>
Example 57: N-methyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo<br>
[1, 5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
!H NMR (400 MHz, CDC13) : 5 2.93 (3H, s), 3.42 (3H, s), 3.9<br>
(3H, s), 6.97-7.01 (2H, m), 7.12 (1H, d, J= 4.4 Hz), 7.61-<br>
7.65 (2H, m), 7.94-7.99 (3H, m), 8.13 (1H, a), 8.55 (1H,<br>
s) , 8.78 (1H, d, J= 3.6  Hz)<br>
MS (ES) m/z = 437 (MH+)<br>
HPLC = 99%<br>
Example 58: N-ethyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo<br>
[1, 5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
lE  NMR (400 MHz, CDC13) : 5 1.23 (3H, t, J= 7.2 Hz), 2.97<br>
(3H, s), 3.82 (2H, q, J= 7.2 Hz), 3.9 (3H, s), 6.98-7.00<br><br>
(2H, m) , 7.14 (1H, d, J- 4 Hz), 7.59-7.60 (1H, m), 7.65<br>
(1H, t, J= 8 Hz), 7.96-8.03 (3H, m), 8.1 (1H, t, J= 2<br>
Hz).8.55 (1H, s), 8.78 (1H, d, J= 4 Hz)<br>
MS (ES) m/z = 451 (MH+)<br>
HPLC = 98%<br>
Example 59: N-methyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-ethane-sulfonamlde<br>
XH NMR (400 MHz, CDC13) : 5 1.41 (3H, t, J= 7.2 Hz), 3.13<br>
(2H, q, J= 7.2 Hz), 3.45 (3H, s), 3.9 (3H, s), 6.98-7.00<br>
(2H, m), 7.12 (1H, d, J= 4.4 Hz), 7.61-7.63 (2H, m), 7.93-<br>
7.98 (3H, m), 8.14 (1H, t, J= 1.2 Hz), 8.55 (1H, s) , 8.78<br>
(1H, d, J= 4 Hz)<br>
MS (ES) m/z = 451 (MH+)<br>
HPLC = 97%<br>
Example 60: N-ethyl-N-{3-[3-(4-methoxybenzoyl)-pyRazolo<br>
[ 1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH  NMR (400 MHz, CDC13) : 5 1.23 (3H, t, J= 7.2 Hz), 1.43<br>
(3H, t, J= 7.2 Hz), 3.12 (2H, q, J= 7.2 Hz), 3.86 (2H, q,<br>
J= 7.2 Hz), 3.91 (3H, s), 6.98-7.00 (2H, m), 7.14 (1H, d,<br>
J= 4 Hz), 7.6-7.65 (2H, m), 7.96-8.02 (3H, m), 8.11 (1H, t,<br>
J= 1.6 Hz), 8.55 (1H, s), 8.78 (1H, d, J= 4 Hz)<br>
MS (SS) m/z = 465 (MH+)<br>
HPLC = 98%<br>
Example 61: N-pRop-2-inyl-N-{3-[3-(4-methoxybenzoyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
\H NMR (400 MHz, CDC13) : 5 1.43 (3H, t, J= 7.2 Hz), 2.48<br>
(1H, t, J= 2.4 Hz), 3.27 (2H, q, J= 7.2 Hz), 3.9 (3H, s),<br><br>
4.55 (2H, d, J= 2.4 Hz), 6.98-7.00 (2H, m), 7.13 (1H, d, J=<br>
4.4 Hz), 7.64 (1H, t, J= 8 Hz), 7.80-7.83 (1H, m), 7.96-<br>
7.98 (2H, m).8.03-8.05 (1H, m), 8.28 (1H, a), 8.55 (1H, s),<br>
8.78 (1H, d, J= 3.6 Hz)<br>
MS (ES) m/z = 475 (MH+)<br>
HPLC = 97%<br>
Example 62: N-pRop-2-inyl-N-{3-[3-(4-methoxybenzoyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.53 (1H, t, J= 2 Hz), 3.11 (3H,<br>
s), 3.87 (3H, s), 4.53 (2H, d, J= 2 Hz), 6.98 (2H, d, J=<br>
8.8 Hz), 7.12 (1H, d, J= 4.4 Hz), 7.63 (1H, t, J= 7.6 Hz),<br>
7.82-7.84 (1H, m), 7.95 (2H, d, J= 8.8 Hz), 8.03 (1H, d, J=<br>
7.6 Hz), 8.31 (1H, t, J= 2 Hz), 8.54 (1H, s), 8.76 (1H, d,<br>
J= 4.4 Hz)<br>
MS (ES) m/z = 461 (MH+)<br>
HPLC = 100%<br>
Example 63: N-methyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
XR  NMR (400 MHz, CDC13) : 5 2.5 (3H, s) , 2.97 (3H, s), 3.46<br>
(3H, s), 7.18 (1H, d, J= 4.4 Hz), 7.34 (2H, d, J= 8.4 Hz),<br>
7.65-7.67 (2H, m), 7.89 (2H, d, J= 8 Hz), 7.98-8.00 (1H,<br>
m), 8.17 (1H, s), 8.58 (1H, s), 8.83 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 421 (MH+)<br>
HPLC = 99%<br>
Example 64: N-ethyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo[1, 5-<br>
a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br><br>
*H NMR (400 MHz, CDC13) : 5 1.23 (3H, t, J= 7.2 Hz), 2.45<br>
(3H, s), 2.96 (3H, s), 3.82 (2H, q, J= 7.2 Hz), 7.15 (1H,<br>
d, J= 4.4 Hz), 7.29-7.3 (2H, m) , 7.58-7.64 (2H, m) , 7.83-<br>
7.85 (2H, m), 7.99-8.02 (1H, m), 8.1 (1H, t, J= 2 Hz), 8.53<br>
(1H, s), 8.79 (1H, d, J= 4.8 Hz)<br>
MS (ES) m/z = 435 (MH+)<br>
HPLC = 96%<br>
Example 65: N-methyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo<br>
[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.41 (3H, t, J= 7.2 Hz), 2.46<br>
(3H, s), 3.12 (2H, q, J= 7.2 Hz), 3.44 (3H, s), 7.13 (1H,<br>
d, J= 4 Hz), 7.31 (2H, d, J- 8.4 Hz), 7.61-7.63 (2H, m) ,<br>
7.85-7.87 (2H, m) , 7.92-7.93 (1H, m) , 8.13-8.14 (1H, m) ,<br>
8.54 (1H, s), 8.79 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 435 (MH+)<br>
HPLC = 98%<br>
Example 66: N-ethyl-N-{3-[3-(4-methylbenzoyl)-pyRazolo[1,5-<br>
a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.22 (3H, t, J= 7.2 Hz), 1.42<br>
(3H, t, J= 7.2 Hz), 2.46 (3H, s), 3.11 (2H, q, J= 7.2 Hz),<br>
3.85 (2H, q, J= 7.2 Hz), 7.15 (1H, d, J= 4.4 Hz), 7.31 (2H,<br>
d, J= 8.2 Hz), 7.60-7.66 (2H, m) , 7.84-7.86 (2H, m), 8 (1H,<br>
d, J= 7.6 Hz), 8.11 (1H, t, J= 1.6 Hz), 8.54 (1H, s), 8.8<br>
(1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 449 (MH+)<br>
HPLC = 100%<br>
Example 67: N-pRop-2-inyl-N-{3-[3-(4-methylbenzoyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br><br>
XH NMR (400 MHz, CDC13) : 5 1.43 (3H, t, J= 7.2 Hz), 2.46<br>
(3H, s), 2.48 (1H, t, J= 2.4 Hz), 3.27 (2H, q, J= 7.2 Hz),<br>
4.54 (2H, d, J= 2.4 Hz), 7.14 (1H, d, J= 4 Hz), 7.31 (2H,<br>
d, J= 8 Hz), 7.63 (1H, t, J= 8 Hz), 7.81-7.86 (3H, m), 8.03<br>
(1H, d, J= 8 Hz), 8.28 (1H, t, J= 2 Hz), 8.54 (1H, s), 8.8<br>
(1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 459 (MH+)<br>
HPLC = 98%<br>
Example 68: N-pRop-2-inyl-N-{3-[3-(4-methylbenzoyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
*H NMR (400 MHz, CDC13) : 5 2.46 (3H, s) , 2.53 (1H, t, J=<br>
2.4 Hz), 3.11 (3H, s), 4.54 (2H, d, J= 2.4 Hz), 7.14 (1H,<br>
d, J= 4 Hz), 7.3 (2H, d, J= 8 Hz), 7.64 (1H, t, J= 8 Hz),<br>
7.83-7.86 (3H, m), 8.03-8.05 (1H, m), 8.31 (1H, t, J= 2<br>
Hz), 8.54 (1H, s), 8.8 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 445 (MH+)<br>
HPLC = 98%<br>
Example 69: N-methyl-N-{3-[3-(benzoyl)-pyRazolo[1,5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonaRaide<br>
XH NMR (400 MHz, CDC13) : 5 2.93 (3H, s), 3.42 (3H, s), 7.15<br>
(1H, d, J= 4.4 Hz), 7.49-7.52 (2H, m), 7.58-7.63 (3H, m),<br>
7.92-7.94 (3H, m), 8.13 (1H, a), 8.54 (1H, s), 8.81 (1H, d,<br>
J= 4.4 Hz)<br>
MS (ES) m/z = 407 (MH+)<br>
HPLC =96%<br><br>
Example 70: N-ethyl-N-{3-[3-(benzoyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
lR  NMR (400 MHz, CDC13) : 5 1.22 (3H, t, J= 7.2 Hz), 2.97<br>
(3H, s), 3.82 (2H, q, J= 7.2 Hz), 7.17 (1H, d, J= 4.4 Hz),<br>
7.49-7.52 (2H, m) , 7.56-7.67 (3H, m), 7.91-7.94 (2H, m),<br>
7.80-8.02 (1H, m), 8.11 (1H, t, J= 2 Hz), 8.53 (1H, s),<br>
8.82 (1H, d, J= 4.4 Hz)	- -<br>
MS (ES) m/z = 421 (MH+)<br>
HPLC =98%<br>
Example 71: N-methyl-N-{3-[3-(benzoyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.39 (3H, t, J= 7.2 Hz), 3.11<br>
(2H, q, J= 7.2 Hz), 3.43 (3H, s), 7.15 (1H, a), 7.47-7.61<br>
(5H, m) , 7.91 (3H, d, J= 7.6 Hz), 8.14 (1H, s), 8.52 (1H,<br>
s), 8.79 (1H, a)<br>
MS (ES) m/z = 421 (MH+)<br>
HPLC = 98%<br>
Example 72: N-ethyl-N-{3-[3-(benzoyl)-pyRazolo[1, 5-a]<br>
pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.23 (3H, t, J= 7.2 Hz), 1.42<br>
(3H, t, J= 7.2 Hz), 1.56 (3H, s), 3.11 (2H, q, J= 7.2 Hz),<br>
3.85 (2H, q, J= 7.2 Hz), 7.17 (1H, d, J= 4.4 Hz), 7.49-7.53<br>
(2H, m), 7.58-7.66 (3H, m), 7.92-7.94 (2H, m) , 8.01 (1H, d,<br>
J= 7.6 Hz), 8.11 (1H, t, J= 1.6 Hz), 8.54 (1H, s), 8.82<br>
(1H, d, J= 4.8 Hz)<br>
MS (ES) m/z = 435 (MH+)<br>
HPLC = 100%<br><br>
Example 73: N-pRop-2-inyl-N-{3-[3-(benzoyl)-pyRazolo [1,5-<br>
a]pyRimidin-7-yl]-phenyl}-ethanesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.43 (3H, t, J= 7.2 Hz), 2.48<br>
(1H, t, J= 2.8 Hz), 3.27 (2H, q, J= 7.2 Hz), 4.54 (2H, d,<br>
J= 2.8 Hz), 7.16 (1H, d, J=4.4 Hz), 7.49-7.52 (2H, m) ,<br>
7.58-7.66 (2H, m), 7.82 (1H, d, J= 8 Hz), 7.93 (2H, d, J=<br>
6.8 Hz), 8.04 (1H, d, J= 8 Hz), 8.29 (1H, a), 8.54 (1H, s) ,<br>
8.81 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 445 (MH+)<br>
HPLC = 97%<br>
Example 74: N-pRop-2-inyl-N-{3-[3-(benzoyl)-pyRazolo [1,5-<br>
a]pyRimidin-7-yl]-phenyl}-methanesulfonamide<br>
lR  NMR (400 MHz, CDC13) : 5 2.53 (1H, t, J= 2.4 Hz), 3.12<br>
(3H, s), 4.54 (2H, d, J= 2.4 Hz), 7.16 (1H, d, J= 4.8 Hz),<br>
7.49-7.53 (2H, m) , 7.58-7.60 (1H, m), 7.65 (1H, t, J= 8<br>
Hz), 7.84-7.86 (1H, m) , 7.92-7.94 (2H, m), 8.04 (1H, d, J=<br>
8 Hz), 8.32 (1H, t, J= 2 Hz), 8.54 (1H, s), 8.82 (1H, d, J=<br>
4.4 Hz)<br>
MS (ES) m/z = 431 (MH+)<br>
HPLC = 97%<br>
Example 75: N-methyl~N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-2-phenylethene-<br>
sulfonamide<br>
XH  NMR (400 MHz, CDC13) : 5 3.35 (3H, s), 6.78 (1H, d, J-<br>
15.5 Hz), 7.13 (1H, d, J= 4.6 Hz), 7.21 (1H, dd), 7.48-7.52<br>
(6H, m), 7.6-7.63 (2H, m), 7.71 (1H, dd), 7.92-7.96 (1H,<br>
m), 3.06 (1H, dd), 8.13 (1H, m).8.53 (1H, m).8.8 (1H, d, J=<br>
4.6 Hz)<br>
MS (ES) m/z =501 (MH+)<br><br>
HPLC = 96.98%<br>
Example 76: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-2,2,2-<br>
tRifluoRoethane-sulfonamide<br>
XH  NMR (400 MHz, CDC13) : 5 3.48 (3H, s), 3.87 (2H, c, J=<br>
9.1 Hz)/ 7.16 (1H, d, J= 4.6 Hz),-7.21 (1H, dd) , 7.65-7.67<br>
(1H, m), 7.68 (1H, s), 7.72 (1H, dd), 7.98-8.02 (1H, m),<br>
8.09 (1H, dd), 8.2 (1H, m).8.7 (1H, s).8.84 (1H, d, J= 4.6<br>
Hz)<br>
MS (ES) m/z = 481 (MH+)<br>
HPLC = 99.05%<br>
Example 77: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1, 5-a]pyRimidin-7-yl]-phenyl}-2-chloRobenzene-<br>
sulfonamide<br>
XR  NMR (400 MHz, CDC13): 5 3.47 (3H, s) , 7.06 (1H, d, J=»<br>
4.6 Hz), 7.19-7.23 (1H, m) , 7.32-7.39 (1H, m) , 7.46-7.57<br>
(4H, m) , 7.7-7.72 (1H, m) , 7.92-8 (3H, m) , 8.09-8.11 (1H,<br>
m) , 8.67 (1H, s), 8.8 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 510 (MH+)<br>
HPLC = 99.81%<br>
Example 78: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-3-<br>
chloRobenzenesulfonamide<br>
lH  NMR (400 MHz, CDC13) : 5 3.27 (3H, s) , 7.11 (1H, d, J=<br>
4.6 Hz), 7.19-7.61 (7H, m) , 7.7-7.72 (1H, m), 7.85 (1H, m),<br>
7.97-8.01 (1H, m), 8.09-8.11 (1H, m), 8.68 (1H, s), 8.81<br>
(1H, d, J= 4.6 Hz)<br><br>
MS (ES) m/z = 510 (MH+)<br>
HPLC = 97.44%<br>
Example 79: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-4-<br>
chloRobenzenesulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.25 (3H, s) , 7.1 (1H, d, J= 4.6<br>
Hz), 7.2-7.24 (1H, m), 7.33-7.37 (1H, m) , 7.4S-7.6 (5H, m) ,<br>
7.72 (1H, dd), 7.85-7.87 (1H, m) , 7.95-8 (1H, m), 8.09-8.11<br>
(1H, m), 8.69 (1H, s).8.82 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 510 (MH+)<br>
HPLC = 99.69%<br>
Example 80: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2,4-dichloRobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.46 (3H, s) , 7.08 (1H, d, J=<br>
4.6 Hz), 7.21 (1H, dd), 7.33 (1H, dd), 7.46-7.59 (3H, m),<br>
7.71 (1H, dd), 7.87-7.98 (3H, Ra), 8.09 (1H, dd) , 8.67 (1H,<br>
s), 8.81 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 543 (MH+)<br>
HPLC = 98.04%<br>
Example 81: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-3,4-dichloRobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.27 (3H, s), 7.11 (1H, d, J=<br>
4.6 Hz), 7.21 (1H, dd), 7.37-7.47 (2H, m) , 7.56-7.62 (2H,<br>
m) , 7.7-7.72 (2H, m), 7.86-7.88 (1H, m), 7.94-7.99 (1H, m) ,<br>
8.09 (1H, dd), 8.67 (1H, s).8.81 (1H, d, J= 4.6 Hz)<br><br>
MS (ES) m/z = 543 (MH+)<br>
HPLC = 98.03%<br>
Example 82: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2-cyanobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.41 (3H, s) , 7.15 (1H, d, J=<br>
4.6 Hz), 7.2 (1H, dd), 7.34-7.39 (1H, m) , 7.53-7.59 (1H,<br>
m), 7.69-7.77 (3H, m) , 7.83-7.87 (1H, m) , 7.91-8.01 (3H,<br>
m) , 8.1 (1H, dd), 8.63 (1H, s).8.79 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 500 (MH+)<br>
HPLC = 99.32%<br>
Example 83: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)~<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-3-cyanobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 3.28 (3H, s), 7.13 (1H, d, J=<br>
4.6 Hz), 7.19-7.22 (1H, m) , 7.33-7.36 (1H, m) , 7.56-7.72<br>
(3H, m) , 7.83-7.97 (5H, m) , 8.09 (1H, d, J= 3.6 Hz), 8.66<br>
(1H, s), 8.81 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 500 (MH+)<br>
HPLC = 96.69%<br>
Example 84: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-4-cyanobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 3.28 (3H, s) , 7.12 (1H, d, J=<br>
4.2 Hz), 7.2-7.32 (3H, m), 7.58 (1H, t, J= 8 Hz), 7.71-7.83<br>
(4H, m), 7.91 (1H, a), 7.99 (1H, d, J= 7.6 Hz), 8.09 (1H,<br>
d, J= 3.3 Hz), 8.68 (1H, s), 8.83 (1H, d, J- 3.9 Hz)<br><br>
MS (ES) m/z = 500 (MH+)<br>
HPLC = 97.9%<br>
Example 85: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-3-nitRobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.3 (3H, s), 7.12 (1H, d, J= 4 . 6<br>
Hz), 7.22 (1H, dd), 7.38-7.43 (1H, m), 7.6 (1H, t, J= 7.9<br>
Hz), 7.7-7.77 (2H, m), 7.86-7.97 (3H, m), 8.09 (1H, dd) ,<br>
8.4-8.5 (2H, m), 8.6 (1H, s).8.8 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 520 (MH+)<br>
HPLC = 99.14%<br>
Example 86: N-methyl-N-{3-[3-(thiophene-2-caRbonyl) -<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-4-nitRobenzene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.3 (3H, s) , 7.13 (1H, d, J= 4.6<br>
Hz), 7.23 (1H, dd, J= 4.8 - 0.9 Hz), 7.32-7.37 (1H, m), 7.6<br>
(1H, t, J= 7.9 Hz), 7.73 (1H, dd, J= 4.8 - 3.6 Hz), 7.82<br>
(2H, d, J= 9.1 Hz), 7.9 (1H, m), 7.95-7.99 (1H, m), 8.07<br>
(1H, dd).8.36 (2H, d, J= 9.1 Hz).8.66 (1H, s).8.83 (1H, d,<br>
J= 4.6 Hz)<br>
MS (ES) m/z = 520 (MH+)<br>
HPLC = 96.18%<br>
Example 87: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2-thiophene-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 3.35 (3H, s), 7.13-7.18 (2H, d),<br>
7.23-7.31 (1H, m) , 7.39-7.46 (2H, m) , 7.58-7.63 (2H, m),<br><br>
7.74-7.77 (1H, m), 7.93 (1H, d, J= 1.5 Hz), 8.06 (1H, dd,<br>
J= 7.9 - 1.2 Hz), 8.14 (1H, m) , 8.72 (1H, s).8.85 (1H, d,<br>
J= 4.3 Hz)<br>
MS (ES) m/z = 481 (MH+)<br>
HPLC = 98.82%<br>
Example 88: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-5-methyl-4-<br>
isoxazolylsulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.3 (3H, s), 3.29 (3H, s), 7.11<br>
(1H, d, J= 4.2 Hz), 7.21 (1H, dd, J= 5.2 - 3.9 Hz), 7.51-<br>
7.55 (1H, m), 7.63 (1H, t, J= 7.9 Hz), 7.71 (1H, dd, J= 5.2<br>
- 1.2 Hz), 7.91-7.94 (2H, m), 8.07 (1H, dd), 8.32 (1H, d,<br>
J= 0.6 Hz).8.7 (1H, s).8.82 (1H, d, J= 4.2 Hz)<br>
MS (ES) m/z = 480 (MH+)<br>
HPLC = 96.78%<br>
Example 89: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2-tRifluoRomethyl-5-<br>
methyl-3-fuRylsulfonamide<br>
2H NMR (400 MHz, CDC13) : 5 2.23 (3H, s), 3.3 (3H, s), 7.11<br>
(1H, d, J= 4.6 Hz), 7.2-7.24 (1H, m) , 7.52-7.66 (2H, m),<br>
7.72 (1H, dd, J= 4.9 - 1.2 Hz), 7.91-7.95 (2H, m), 8.07<br>
(1H, dd), 8.67 (1H, s), 8.82 (1H, d, J= 4.2 Hz)<br>
MS (ES) m/z = 547 (MH+)<br>
HPLC = 98.88%<br>
Example 90: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-6-(moRpholin-4-yl)-<br>
3-pyRidylsulfonamide<br><br>
XH NMR (400 MHz, CDC13) : 5 3.24 (3H, s) , 3.62-3.67 (4H, m) ,<br>
3.78-3.82 (4H, m) , 6.55 (1H, d, J= 9.1 Hz), 7.14 (1H, d, J=<br>
4.2 Hz), 7.21 (1H, dd, J= 4.9 - 3.6 Hz), 7.36-7.4 (1H, m) ,<br>
7.53-7.6 (2H, m), 7.72 (1H, dd, J= 4.9 - 1.2 Hz), 7.93-8.01<br>
(2H, m).8.1-8.12 (1H, m).8.39 (1H, d, J= 2.4 Hz).8.69 (1H,<br>
s).8.81 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 561 (MH+)<br>
HPLC = 98.7%<br>
Example 91: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-2,4-dimethyl-5-<br>
thiazolylsulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.22 (3H, s) , 2.69 (3H, s) , 3.35<br>
(3H, s), 7.11 (1H, d, J= 4.6 Hz), 7.2 (1H, dd), 7.43-7.47<br>
(1H, m), 7.59 (1H, m), 7.71 (1H, dd), 7.93-7.94 (1H, m) ,<br>
7.97-8.02 (1H, m).8.09 (1H, dd, J- 3.7 - 1.1 Hz).8.68 (1H,<br>
s).8.81 (1H, d, J= 4.6 Hz)<br>
MS (ES) m/z = 510 (MH+)<br>
HPLC = 99.18%<br>
Example 92:   N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRa zolo[1,5-a]pyRimidin-7-yl]-phenyl}-cyclopRopyl-<br>
sulfonamide<br>
lE  NMR (400 MHz, CDC13) : 5 0.95-1.06 (2H, m), 1.09-1.18<br>
(2H, m) , 2.4-2.51 (1H, m), 3.44 (3H, s), 7.16 (1H, d, J=<br>
4.6 Hz), 7.19-7.23 (1H, m) , 7.58-7.73 (3H, m), 7.96 (1H,<br>
m), 8.11 (1H, m), 8.16 (1H, m).8.71 (1H, s).8.82 (1H, d, J=<br>
4.2 Hz)<br>
MS (ES) m/z = 439 (MH+)<br>
HPLC = 96.7%<br><br>
Example 93: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[ 1,5-a]pyRimidin-7-yl]-phenyl}-bensylsulfonamide<br>
2H NMR (400 MHz, CDC13) : 5 3.21 (3H, s) , 4.39 (2H, s), 7.1<br>
(1H, d, J= 4.6 Hz), 7.2-7.24 (1H, m), 7.33-7.47 (6H, m) ,<br>
7.54-7.6 (1H, m), 7.71 (1H, d, J= 4.9 Hz), 7.87-7.92 (2H,<br>
m) , 8.12 (1H, d, J= 3.3 Hz), 8.74 (1H, s).8.83 (1H, d, J=<br>
4.6	Hz)<br>
MS (ES) m/z = 489 (MH+)<br>
HPLC = 97.95%<br>
Example 94: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-ylJ-phenyl}—vinylsulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 3.32 (3H, s), 6.08 (1H, d, J=<br>
9.7	Hz), 6.26 (1H, d, J= 16.4 Hz), 6.51 (1H, dd, J= 16.4 -<br>
9.7 Hz), 7.15 (1H, d, J= 4.2 Hz), 7.2 (1H, dd, J= 4.8 - 3.9<br>
Hz), 7.53-7.64 (2H, m),   1.1   (1H, dd, J- 4.8 - 1.2 Hz),<br>
7.94-7.98 (1H, m), 8.06-8.11 (2H, m)<br>
MS (ES) m/z = 425 (MH+)<br>
HPLC = 97.53%<br>
Example 95: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-3, 5-dimethyl-4-<br>
isoxazolylsulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 2.12 (3H, s), 2.33 (3H, s), 3.31<br>
(3H, s), 7.1 (1H, d, J= 4.5 Hz), 7.19-7.23 (1H, m), 7.52-<br>
7.66 (2H, m), 7.71 (1H, d, J= 5.5 Hz), 7.93-7.96 (2H, m),<br>
8.07 (1H, d, J= 3.6  Hz), 8.69   (1H, s).8.82 (1H, d, J= 4.2<br>
Hz)<br>
MS (ES) m/z = 494 (MH+)<br>
HPLC = 99.17%<br><br>
Example 96: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-l,3,5-tRimethyl-4-<br>
pyRazolylsulfonamide<br>
:H NMR (400 MHz, CDC13) : 6 2.09 (3H, s), 2.1 (3H, s), 3.24<br>
(3H, s), 3.7 (3H, s), 7.1 (1H, d, J= 4.2 Hz), 7.2 (1H, dd,<br>
J= 4.8 - 3.6 Hz), 7.45-7.59 (2H, Ra), 7.71 (1H, dd), 7.9-<br>
7.98 (2H, m), 8.09-8.11 (1H, m), 8.67 (1H, s), 8.8 (1H, d,<br>
J= 4.2 Hz)<br>
MS (ES) m/z = 507 (MH+)<br>
HPLC = 94.68%<br>
Example 97: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-pRopanesulfonamide<br>
1H  NMR (400 MHz, CDCI3) : 5 1.06 (3H, t, J= 7.5 Hz), 1.92-<br>
1.97 (2H, m), 3.02-3.08 (2H, m), 3.43 (3H, s), 7.16 (1H, d,<br>
J= 4.2 Hz), 7.19-7.23 (1H, m) , 7.62-7.64 (2H, m), 7.72 (1H,<br>
m), 7.93-7.97 (1H, m) , 8.11-8.14 (2H, m).8.71 (1H, s).8.83<br>
(1H, d, J= 4.6  Hz)<br>
MS (ES) m/z = 441 (MH+)<br>
HPLC = 97.75%<br>
Example 98: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-butanesulfonamide<br>
1H  NMR (400 MHz, CDCI3) : 5 0.93 (3H, t, J= 7.5 Hz), 1.44<br>
(2H, m) , 1.77-1.89 (2H, m) , 3.04-3.11 (2H, m), 3.43 (3H,<br>
s), 7.16 (1H,. d, J= 4.6  Hz), 7.2 (1H, dd, J= 5.2 - 3.9 Hz),<br>
7.61-7.64 (2H, m) , 7.71 (1H, dd, J= 5.2 - 1.2 Hz), 7.91-<br>
7.96 (1H, m).8.1 (1H, dd, J= 3.9 - 1.2 Hz).8.14 (1H, m).8.7<br>
(1H, s).8.82 (1H, d, J= 4.3 Hz)<br><br>
MS (ES) m/z = 455 (MH+)<br>
HPLC = 98.54%<br>
Example 99: N-methyl-N-{3-[3-(thiophene-2-caRbonyl)-<br>
pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-cyclopentylmethane-<br>
sulfonaRaide<br>
XH NMR (400 MHz, CDC13) : 5 1.23-1.34 (2H, m) , 1.56-1.66<br>
(4H, m), 1.95-2.03 (2H, m), 2.32-2.44 (1H, m), 3.08 (2H, d,<br>
J= 7 Hz), 3.42 (3H, s) , 7.16 (1H, d, J= 4.2 Hz), 7.2 (1H,<br>
dd, J= 4.9 - 3.9 Hz), 7.61-7.63 (2H, m), 7.71 (1H, dd, J=<br>
4.9 - 1.2 Hz).7.91-7.96 (1H, m).8.09-8.14 (2H, m).8.7 (1H,<br>
s).8.82 (1H, d, J= 4.2 Hz)<br>
MS (ES) m/z = 481 (MH+)<br>
HPLC = 96.43%<br>
Example 100: N-{3-[3-(5-methyl-[1,2,4]oxadiazol-3-yl)-<br>
pyRazolo [1,5-a]pyRimidin-7-yl]-phenyl}-methane-sulfonamide<br>
XH NMR (400 MHz, CDCI3) : 5 2.71 (3H, s) , 3.12 (3H, s), 7.08<br>
(1H, d, J= 4.4 Hz), 7.1 (1H, a), 7.43-7.46 (1H, m), 7.57<br>
(1H, t, J= 7.6 Hz), 7.80-7.83 (1H, m), 7.95 (1H, t, J= 2<br>
Hz), 8.69 (1H, s), 8.8 (1H, d, J= 4.4 Hz)<br>
MS (ES) m/z = 371 (MH+)<br>
HPLC = 94%<br>
Example 101: N-ethyl-N-{3-[3-(5-methyl-[1,2,4]oxadiazol-3-<br>
yl)-pyRazolo[1,5-a]pyRimidin-7-yl]-phenyl}-methane-<br>
sulfonamide<br>
XH NMR (400 MHz, CDC13) : 5 1.21 (3H, t, J= 7.2 Hz), 2.69<br>
(3H, s), 2.95 (3H, s) , 3.81 (2H, q, J= 7.2 Hz), 7.1 (1H, d,<br>
J= 4.8 Hz), 7.56-7.58 (1H, m), 7.64 (1H, t, J= 8 Hz), 8.04<br><br><br><br><br><br><br><br>
WE CLAIM:<br><br>
wheRein<br>
Ri is selected fRom the gRoup consisting of alkyl (C;L-C6) ,<br>
alkenyl (C2-C6) ,  co, co, o-tRifluoRoalkyl (C!-C6) ,  cycloalkyl (C3-<br>
C6),   cycloalkyl (C3-C6) alkyl (Ci-C6) ,   -O-alkyl (Ci-C6) ,        -NH-<br>
alkyl (Ci-C6) , -N (dialkyl (d-C6) ) , alkyl (d-C6)-O-alkyl (Ci-C6) ,<br>
alkyl (Ci-C6) -NH-alkyl (Ci-C6) ,  alkyl (Ci-C6) -N (dialkyl (CL-C6) ) ,<br>
phenyl, phenyl monosubstituted by chloRine, —CN, oR — NO2,<br>
phenyl  disubstituted  by  chloRine,   phenylalkyl(Ci-C6) ,<br>
phenylalkenyl (C2-C6) ,  fuRyl,  fuRyl substituted by 1 oR 2<br>
substituents   selected   fRom   alkyl (Ci-C6)   and   — CF3,<br>
isoxazolyl, isoxazolyl substituted by 1 oR 2 alkyl (Ci-C6) ,<br>
pyRazolyl, pyRazolyl substituted by 1, 2 oR 3 alkyl(Ci-C6) ,<br>
thienyl,  thiazolyl,  thiazolyl  substituted  by  1  oR  2<br>
alkyl (Ci-C6) ,  pyRidyl  and  pyRidyl  substituted  by  4-<br>
moRpholinyl;<br>
R2  is  selected  fRom  the  gRoup  consisting  of  hydRogen,<br>
alkyl (Ci-Ce) ,      alkenyl (C2-C6) ,     alkynyl (C2-C6)      and<br>
cycloalkyl (C3-C6) ;<br>
oR Ri and R2 foRm a cycle having the stRuctuRe:<br><br><br>
wheRein n is an integeR 1, 2 oR 3;<br>
R3 is  selected fRom the  gRoup consisting of hydRogen,<br>
halogen,   alkyl (Ci-C6) ,   cycloalkyl (C3-C6) ,  alkenyl (C2-C6) ,<br>
alkynyl(C2-C6) , -O-alkyl (Ci-C6) , halo-alkyl (Ci-C6) , -CN, -S02-<br>
R4,  -NH-R4,  -NR4R5,  -COR6,  -CO-NHR6,  -COOR6,  -C(NR7)R6,<br>
phenyl, [ 1,2,4] oxadiazolyl and [ 1,2,4] oxadiazol substituted<br>
by alkyl (Ci-C6) ;<br>
R4  and  R5  aRe  independently  selected  fRom  the  gRoup<br>
consisting of alkyl (Ci-C6) and cycloalkyl (C3-C6) ;<br>
R6 is  selected fRom the gRoup consisting of hydRogen,<br>
alkyl (Ci-C6) ,  alkenyl (C2-C6) ,  alkynyl (C2-C6) ,  cycloalkyl(C3-<br>
C6) , phenyl, phenyl substituted by 1 substituent selected<br>
fRom  fluoRine,  alkyl (Ci-C6)  and  -O-alkyl (Ci-C6) ,  fuRyl,<br>
thienyl, thiazolyl and pyRidyl;<br>
R7 is selected fRom the gRoup consisting of alkyl (Ci-C6) ,<br>
cycloalkyl (C3-C6) ,   -OH,   -O-alkyl (Ci-Ce) ,   alkyl (Ci-C6) -O-<br>
alkyl (Ci-C6) ,    alkyl (Ci-C6) -NH-alkyl (Ci-C6) ,    alkyl (Cx-C6)-<br>
N(dialkyl(Ci-C6) ) ,  phenyl,  fuRyl,  thienyl,  thiazolyl and<br>
pyRidyl; and<br>
R8 is hydRogen;<br>
with the pRoviso that simultaneously:<br>
Ri may not be p-tolyl and R2 methyl and R3 benzoyl; and<br>
Ri may not be p-tolyl and R2 ethyl and R3 fuRyl-2-caRbonyl.<br>
2)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
cyano gRoup.<br>
3)	- A compound as claimed in claim 2, wheRein Ri is<br>
selected fRom the gRoup consisting of methyl, ethyl, n-<br>
pRopyl, i-pRopyl, n-butyl, phenyl and 4-methoxyphenyl; and<br><br>
R2 ■ is selected fRom the gRoup consisting of methyl, ethyl,<br>
n-pRopyl, i-pRopyl, n-butyl, cyclopRopyl and 2-pRopynyl.<br>
4)	- A compound as claimed in claim 2, wheRein Ri and<br>
R2 jointly foRm a 1,3-pRopylene gRoup.<br>
5)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
thiophene-2-caRbonyl gRoup.<br>
6)	- A compound as claimed in claim 5, wheRein Ri is<br>
selected fRom the gRoup consisting of methyl, ethyl, n-<br>
pRopyl, i-pRopyl, n-butyl, 2-phenylethenyl, 2,2,2-<br>
tRifluRoethyl, phenyl, 2-chloRophenyl, 3-chloRophenyl, 4-<br>
chloRophenyl, 2,4-dichloRophenyl, 3,4-dichloRophenyl, 2-<br>
cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methoxyphenyl,<br>
3-nitRophenyl, 4-nitRophenyl, 2-thienyl, 5-methyl-4-<br>
isoxazolyl, 5-methyl-2-tRifluoRomethyl-3-fuRyl, 4-(4-<br>
moRpholinyl)-3-pyRidyl,	2,4-dimethyl-5-thiazolyl,<br>
cyclopRopyl, benzyl, vinyl, 3,5-dimethyl-4-isoxazolyl,<br>
1,3,5-tRimethyl-4-pyRazolyl and cyclopentylmethyl; and R2 is<br>
selected fRom the gRoup consisting of hydRogen, methyl,<br>
ethyl, n-pRopyl, i-pRopyl, n-butyl, cyclopRopyl and 2-<br>
pRopynyl.<br>
7)	- A compound as claimed in claim 5 wheRein Ri and<br>
R2 jointly foRm a 1,3-pRopylene gRoup.<br>
8)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
benzoyl gRoup.<br><br>
9)	- A compound as claimed in claim 8 wheRein Ri is<br>
selected fRom the gRoup consisting of methyl and ethyl; and<br>
R2 is selected fRom the gRoup consisting of methyl, ethyl<br>
and 2-pRopinyl.<br>
10)	- A compound as claimed in claim 1, wheRein Rx and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
4-fluoRobenzoyl gRoup.<br>
11)	- A compound as claimed in claim 10 wheRein Rx is<br>
selected fRom the gRoup consisting of methyl and ethyl; and<br>
R2 is selected fRom the gRoup consisting of methyl, ethyl<br>
and 2-pRopinyl.<br>
12)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
4-methylbenzoyl gRoup.<br>
13)	- A compound as claimed in claim 12 wheRein Ri is<br>
selected fRom the gRoup consisting of methyl and ethyl; and<br>
R2 is selected fRom the gRoup consisting of methyl, ethyl<br>
and 2-pRopinyl.<br>
14)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
4-methoxybenzoyl gRoup.<br>
15)	- A compound as claimed in claim 14 wheRein R]. is<br>
selected fRom the gRoup consisting of methyl and ethyl; and<br>
R2 is selected fRom the gRoup consisting of methyl, ethyl<br>
and 2-pRopinyl.<br><br>
16)	- A compound as claimed in claim 1, wheRein Rx and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
5-methyl-l,2,4-oxadiazol-3-yl gRoup.<br>
17)	- A compound as claimed in claim 16 wheRein Ri is<br>
methyl and R2 is selected fRom the gRoup consisting of<br>
hydRogen and ethyl.<br>
18)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
pyRidyl-2-caRbonyl gRoup.<br>
19)	- A compound as claimed in claim 18 wheRein R]. is<br>
selected fRom the gRoup consisting of methyl and ethyl; and<br>
R2 is selected fRom the gRoup consisting of methyl, ethyl<br>
and 2-pRopinyl.<br>
20)	- A compound as claimed in claim 1, wheRein Ri and<br>
R2 aRe independently as defined in foRmula (I) and R3 is a<br>
pyRidyl-4-caRbonyl gRoup.<br>
21)	- A compound as claimed in claim 20 wheRein Rx is<br>
selected fRom the gRoup consisting of methyl and ethyl; and<br>
R2 is selected fRom the gRoup consisting of methyl, ethyl<br>
and 2-pRopinyl.<br>
22)	- A compound as claimed in claims 2 and 3, wheRein<br>
said compound is selected fRom the gRoup consisting of:<br>
N-[ 3-(3-cyano-pyRazolo[ 1, 5-a] pyRimidin-7-yl)-phenyl] -N-<br>
methyl-methanesulfonamide;<br>
N-[ 3-(3-cyano-pyRazolo[ 1, 5-a] pyRimidin-7-yl)-phenyl] -Isl-<br>
et hyl-me thane sulfonamide;<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
33) -A pRocess foR pRepaRing a compound of foRmula (I)<br>
oR a phaRmaceutically acceptable salt theReof, as claimed<br>
in claim 1, compRising Reacting inteRmediate (II):<br><br>
wheRein Rx and R2 aRe as defined in (I) and Q is an<br>
appRopRiate leaving gRoup selected fRom the gRoup<br>
consisting of N (dialkyl (Ci-C6) ) , alkylthio (Ci-C6) and<br>
alkoxy(Ci-C6) , with inteRmediate (III):<br><br>
wheRein R3 is as defined in (I) and alteRnatively, tReatment<br>
of the compounds of claim 1, in the foRm of fRee base, with<br>
an acid to foRm a salt theReof.<br>
34) - A pRocess as claimed in claim 33, compRising<br>
utilizing the inteRmediate of foRmula (II) wheRe Q is<br>
selected fRom the gRoup consisting of dimethylamino,<br>
methylthio and methoxy.<br><br>
35) - A composition compRising a compound of claim 1 in<br>
association with a theRapeutically ineRt caRRieR such as:<br>
(i) wateR, glycols, oils, alcohols, flavoRing agents,<br>
pReseRvatives, and coloRing agents, and mixtuRes theReof,<br>
in the case of oRal liquid pRepaRations such as<br>
suspensions, solutions, emulsions, elixiRs, and aeRosols;<br>
oR<br>
(ii) staRch, sugaRs, micRocRystalline cellulose,<br>
diluents, gRanulating agents, lubRicants, bindeRs, and<br>
disintegRating agents, and mixtuRes theReof, in the case of<br>
oRal solid pRepaRations such as powdeRs, capsules, and<br>
tablets.<br>
36)- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing<br>
diseases associated with GABAA ReceptoR modulation in a<br>
mammal.<br>
37)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing<br>
diseases associated with α1-GABAA ReceptoR modulation in a<br>
mamma1.<br>
38)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing<br>
diseases associated with α2-GABAA ReceptoR modulation in a<br>
mammal.<br>
39)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing<br>
anxiety in a mammal.<br><br>
40)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing<br>
epilepsy in a mammal.<br>
41)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing sleep<br>
disoRdeRs in a mammal.<br>
42)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR tReating oR pReventing<br>
insomnia in a mammal.<br>
43)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR inducing sedation-hypnosis<br>
in a mammal.<br>
44)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR inducing anesthesia in a<br>
mamma1.<br>
45)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR modulating the necessaRy<br>
time to induce sleep and its duRation in a mammal.<br>
46)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR inducing muscle Relaxation<br>
in a mammal.<br>
47)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR pRepaRing a medicament foR<br><br>
tReating  oR  pReventing  diseases  associated  with  GABAA<br>
ReceptoR modulation.<br>
48)	- The composition as claimed in claim 47, wheRein<br>
the diseases aRe associated with α1-GABAA oR α2-GABAA<br>
ReceptoR modulation.<br>
49)	- The composition as claimed in claim 35, wheRein<br>
said composition is useful foR pRepaRing a medicament foR<br>
tReating oR pReventing anxiety, epilepsy, sleep disoRdeRs,<br>
insomnia, foR inducing sedation-hypnosis, anesthesia oR<br>
muscle Relaxation oR foR modulating the necessaRy time to<br>
include sleep and its duRation.<br>
50)	- A pRocess foR pRepaRing the inteRmediate of<br>
foRmula (VII):<br><br>
wheRein R1 is as descRibed in (I), chaRacteRized by the<br>
Reaction of the inteRmediate of foRmula (IV):<br><br><br>
wheRein R1. is as descRibed above, with N,N-dimethylfoRmamide<br>
dimethyl acetal.<br>
51)  - A pRocess foR pRepaRing the inteRmediate of<br>
foRmula (VII): <br>
wheRein R1 is as descRibed in (I) , chaRacteRized by the<br>
Reaction of N-(3-acetylphenyl)-2,2,2-tRifluoRoacetamide<br>
(VIII):<br><br>
and N,N-dimethylfoRmamide dimethyl acetal, followed by the<br>
foRmation of sulfonamide by Reaction with the coRResponding<br>
sulfonic acid chloRide.<br><br>
The present invention discloses compounds of formula I:<br><br>
wherein R1, R2 and R3 are as defined in the specification<br>
having specific affinity for the GABAA receptor, useful in<br>
the treatment and prevention of diseases modulated by the<br>
α1- and α2-GABAA receptors.<br>
The invention is also for the process for preparation of<br>
these compounds and compositions comprising them.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1LT0xOUC0yMDA1LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">2638-KOLNP-2005-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1LT0xOUC0yMDA1LUZPUk0gMjcucGRm" target="_blank" style="word-wrap:break-word;">2638-KOLNP-2005-FORM 27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAxMy5wZGY=" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtZ3BhLnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjYzOC1rb2xucC0yMDA1LWdyYW50ZWQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">2638-kolnp-2005-granted-specification.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="231345-a-radio-transmission-apparatus-and-a-method-for-transmission-power-control-in-a-dedicated-physical-channel.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="231347-emulsifiable-myco-chemical-herbicide-and-process-for-the-preparation-thereof.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>231346</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2638/KOLNP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>10/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>06-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>04-Mar-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>20-Dec-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>FERRER INTERNACIONAL, S.A.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>GRAN VIA CARLOS III, 94, E-08028 BARCELONA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>PALOMER, ALBERT</td>
											<td>ALMERIA 23, E-08014 BARCELONA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>ANGLADA,LUIS</td>
											<td>BRUCH, 111, E-08009, BARCELONA</td>
										</tr>
										<tr>
											<td>3</td>
											<td>PRINCEP MARTA</td>
											<td>VENTURA PLAJA 30-32, E-08028 BARCELONA</td>
										</tr>
										<tr>
											<td>4</td>
											<td>GUGLIETTA, ANTONIO</td>
											<td>MONISTROL, 12, E-08970 SANT JOAN DESPI</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 487/04</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2004/008208</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-07-22</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>200301746</td>
									<td>2003-07-24</td>
								    <td>Spain</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/231346-n-3-3-substituted-pyrazolo-1-5-a-pyrimidin-7-yl-phenyl-sulfonamides-process-for-their-preparation-and-compositions-comprising-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:13:02 GMT -->
</html>
